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Abstract 
 
The Pulmonary route has been traditionally used to treat diseases of the 
respiratory tract. However, important research within the last two decades have 
shown that in addition to treating local diseases, a wide range of systemic diseases 
can be treated by delivering drugs to the lungs. The recent FDA approval to market 
Exubera®, an inhalable form of insulin developed by Pfizer, to treat Diabetes, may 
just be the stepping stone that the pharmaceutical industry needs to market other 
drugs to treat systemic diseases via the lungs. However, this technology still needs 
repeated drug doses to control glucose levels, as the inhaled drug is cleared rapidly. 
Technologies have been developed where inhaled particles are capable of 
controlled release of drug from the lungs. An important feature of these technologies 
is the large geometric size of the particles that makes it difficult for the lung 
macrophages to clear these particles, which results in longer residence times for the 
particles in the lungs. Owing to the porosity, these particles have lower densities 
making them deliverable to the deep lungs. However, no modulation of drug release 
can be achieved with these technologies when more drug release may be required. 
This additional requirement can only be assuaged by additional dosing of the drug 
formulation, which can have undesirable effects due to excess loading of excipients 
in the lungs. 
In an attempt to bring about modulation of release from long residence time 
particles, a novel concept was developed in our laboratory that has been termed as 
 iii 
the Agglomerated Vesicle Technology (AVT). Liposomes with encapsulated drug 
were agglomerated using well known cross linking chemistries to form 
agglomerates in the micron sized range. The large particles exhibited aerodynamic 
sizes in the respirable size range with minimal damage to the particles upon 
nebulization. By breaking the cross links between the liposomes with a cleaving 
agent, it was anticipated that triggered release of drug from the AVT particles could 
be achieved. In vivo studies done in healthy rabbits showed that post-administration 
modulation of drug release is possible from the AVT particles after the introduction 
of the cleaving agent. 
   This study has important implications for the future development of this 
technology, where the AVT particles can be made “sensitive” to the product of 
disease. It is envisaged that a single dose of AVT containing the appropriate drug 
when administered to the lungs would maintain drug levels at a controlled rate over 
an extended period of time. When the need for more drug arises, the product of the 
disease would trigger the AVT particles to release more drug as needed to control 
the condition, thus eliminating the need for repeated drug doses and improved 
compliance amongst patients.   
 iv 
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Chapter 1 
Introduction 
1.1. Pulmonary route of drug delivery 
Inhalation therapy has been used for more than 4000 years primarily for 
the treatment of respiratory diseases. Ancient therapies have included inhaling 
smoke emanating from lit medicinal concoctions to inhaling vapors released 
from aromatic plants [1]. Aerosolized delivery of drugs to the lungs has greatly 
improved the treatment of various respiratory diseases. As examples, anti-
inflammatory and bronchodilator aerosol medications have been the cornerstone 
of asthma treatment; and antibiotics have been used for treating cystic fibrosis 
and lung infections.  
 The pulmonary drug delivery area has grown tremendously since the 
mid 20th century into a multi-billion dollar industry. During the past two 
decades, the lungs have been considered a promising route for the 
administration of therapeutics not only for the treatment of local pulmonary 
diseases (e.g. asthma) but also for the treatment of systemic conditions (e.g. 
diabetes). This increased interest in pulmonary drug delivery is based on (1) the 
high bioavailability of protein and peptide drugs when delivered to the 
respiratory system, (2) the large surface area (140 m2) of the adult lung, in 
intimate contact with the circulatory system via the alveoli, (3) the equivalence of 
inhalation to arterial injection, and (4) the consequent avoidance of first pass 
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hepatic and renal effects. Compounds with high potential for delivery by the 
respiratory route include insulin, cyclosporine, interferon, antitrypsin, protease 
inhibitors, deoxyribonucleases, recombinant adenoviruses and many more [2]. 
Further, in the wake of recent terrorist attacks on the United States, there has 
been a renewed interest in protection against biological agents, many of which 
infect via the respiratory route, and are therefore best protected against by the 
respiratory delivery of anti-infectives and antibiotics [3]. 
It has long been recognized that the lung allows high systemic 
bioavailability of proteins like insulin [4]. This has driven the development of a 
number of inhaled insulin projects [5]. The goal for a systemically active, inhaled 
drug is to reach the deep lung region in order to be transported into the blood 
stream. In order to reach the deep lung, particles must have an aerodynamic 
diameter (Daer) in the 1 – 5 µm range. The aerodynamic diameter is related to the 
geometric diameter (Dgeo) as Daer=Dgeo·ρ0.5, where ρ is the specific gravity of the 
particle. For particles with specific gravity = 1 (the case for most solid 
pharmaceutical powders), the geometric diameter and the aerodynamic diameter 
are identical. Therefore, particles that are optimal for deep lung delivery will 
often also have a geometric diameters in the 1 – 5 µm range, putting them in the 
size range where pulmonary macrophage activity is the highest (this is not 
surprising, since the macrophage system was probably optimized by 
evolutionary processes to eliminate inhaled particles that reach the deep lung). 
Solid drug particles optimized for drug delivery to the deep lung would 
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therefore meet the same fate, and be cleared by macrophage uptake and likely 
pass via the pores of Kohn into the circulatory system and thence to the 
reticuloendothelial system (RES). Only the portion of the particles that were not 
thus affected would contribute to drug delivery. A secondary consequence of 
this rapid macrophage uptake and clearance is the short duration of delivery for 
an inhaled drug, since the delivery must take place before macrophage mediated 
clearance of the particles takes place. Typically, this time frame is around an 
hour. 
However, a breakthrough discovery was made around 1997, when 
Edwards et al. [6] recognized that the macrophage uptake system relies on the 
geometric diameter of particles to recognize and clear them, while the deposition 
of the particles in the lung depends on the aerodynamic diameter of the particles. 
They fabricated light, porous particles that were physically quite large (10’s of 
microns) but had the aerodynamic behavior of smaller (1-3 microns) particles. 
These porous particles, originally fabricated from PLA/PLGA polymers loaded 
with insulin were shown to reside in the rat lung for extended periods of time, 
and provide extended release of insulin for up to 72 hours.  
  
1.2. Proposed research aims 
While these advances permit controlled release of the drug at some pre-
programmed rate, they do not permit modulation of this rate on demand. To 
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address this need, our group has advanced a new technology [7] based on 
chemically agglomerated vesicles (the AVT technology) that allows the 
modulation of the release rate from long-residence time particles deposited in the 
lung. The AVT particles exhibited controlled release patterns of the antibiotic 
Ciprofloxacin in vitro. The modulation was accomplished by cleavage of the 
linkages agglomerating the vesicles, both disrupting the vesicular structure and 
releasing internal surface area for transport of the drug across the vesicle wall. 
However, the cleaving agents used to trigger the release from the first generation 
of AVT particles are not acceptable for in vivo applications. Therefore, a new 
generation of in vivo compatible agglomerated liposomes was recently 
developed based on PEG conjugate containing a dithiobenzyl (DTB) urethane 
linkage cleavable by cysteine. It has been shown in vitro that the release rate of 
encapsulated compounds from these carriers can be modulated by the addition 
of mild thiolytic agents such as cysteine [8]. While there are low levels of cysteine 
and glutathione in the lung, capable of causing some cleavage of disulfide links 
between nanoparticles, the further addition of a free thiol as a “cleaver” dose 
would trigger the accelerated release of drug by cleavage of the inter-particle 
links and liberation of free nanoparticles. When administered in vivo, these 
particles facilitated post-administration-modulation of drug release. Thus, 
insulin release with the possibility of controlled post-administration changes in 
the release rate was demonstrated for the first time [9]. However, continuing 
concerns about the cleavage of this linkage by endogenous cysteine remained.  
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This therefore led us to seek alternative linkages that would not cleave in the 
presence of endogenous thiols, but would cleave upon the administration of 
exogenous cysteine, at levels higher than that present normally in the body. The 
availability of such a linkage would facilitate more complete control over the 
release of drug from the nanostructured AVT particles. 
In this study, it is sought to extend the application of the AVT platform 
and demonstrate in a healthy animal model the controlled and cysteine-mediated 
modulation of drug release from agglomerates in the lungs. As a test drug, 
Ciprofloxacin has been used in this study.  
The following specific aims were addressed to test the controlled and 
modulated drug release features of the Agglomerated Vesicle Technology (AVT): 
1) In vitro characterization of the agglomerates based on size/structure 
(utilizing light scattering and microscopy techniques), and release 
characteristics to select the optimal conditions for making the AVT to 
be tested in vivo. 
2) To test in a rabbit model the controlled and modulated release 
characteristics of different AVT and liposomal formulations of 
Ciprofloxacin after instillation in the lungs. 
3) To evaluate acute toxicity issues of the AVT by instilling Ciprofloxacin 
formulation of AVT and liposomes in the lungs of rats and evaluate 
inflammation by histology and assay of cytokines. 
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Chapter 2 
Background and Significance 
2.1. Respiratory tract physiology 
The success of a therapy using aerosolized medications depends on its 
ability to deliver sufficient drug to appropriate sites in the lungs with minimal 
side effects. This in turn depends on aspects of airway anatomy and physiology, 
which change with disease and age [10, 11]. 
The respiratory tree includes (1) the conducting airways with thick walls 
consisting of the trachea, the 2 bronchi and the bronchioles, and (2) the alveoli 
(where gas exchange occurs) across thin walls. The trachea is a flexible tube 
extending from the larynx. It is composed of 3 layers as shown in figure 1a: 1) the 
mucosa made up of goblet cells and ciliated epithelium, 2) the submucosa which 
is a connective tissue, and 3) the adventitia, which is the outermost layer made of 
C-shaped rings of hyaline cartilage. The trachea bifurcates into the left and right 
bronchi which continue subdividing into the bronchioles (figure 1b). The tissue 
walls of the bronchi and the bronchioles mimic that of the trachea. However, as 
the conducting airways become smaller, structural changes occur. There is a lack 
of cartilage support and increased amount of smooth muscle. Additionally, the 
epithelium is cuboidal without mucus-producing cells. The respiratory zone is 
defined by the presence of alveoli. The terminal bronchioles feed into the 
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respiratory bronchioles which lead in to alveolar ducts, then to terminal clusters 
or alveolar sacs composed of alveoli. The respiratory zone accounts for most of 
the lung’s volume since it consists of 300 million alveoli providing a tremendous 
surface area for gas exchange. 
The airways bifurcate more than 17 times resulting in an enormous 
surface area of the alveolar region. A laborious study conducted by Weibel [13] 
extracted the dimensions in different regions of the lungs summarized in figure 
2a. In many recent studies, the alveolar surface area of human adults was 
estimated to be ~100 m2 [14, 15], which represents half a tennis court. The total 
lung capacity averages 6.7 and 4.9 liters in men and women, respectively [15]. It 
 
 
Figure 1. (a) The wall of the trachea and (b) the upper respiratory tract consisting of 
the trachea, the bronchi and the bronchioles [12] 
(a) (b) 
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should be noted that under normal (tidal) breathing conditions the lungs are half 
empty. The conducting zone contains 4% of the inhaled air, and the alveoli the 
rest. 
A drug molecule administered to the lungs must overcome 5 barriers in 
order to reach blood circulation [16]:  
1. Surfactant: The lung surfactant spreads at the air/water interface. It is a 
single molecule thick in most places with the fatty acid tails facing the air 
side but it may cause large molecules to aggregate which could enhance 
engulfment and digestion by airspace macrophages. The surfactant’s role 
is to reduce the surface tension of the alveolar walls in order to prevent 
the complete collapse of the airways during exhalation. 
2. Surface lining fluid: It is the reservoir for lung surfactant. It has similar 
composition as plasma. In the airways the thickness of the lining fluid is 
between 5-10 μm, and in the alveoli 0.05-0.2 μm. The fluid in the 
conductive airways contains mucus which flows toward the trachea by 
the action of cilia. Mucus is absent in the alveolar fluid.  
3. Epithelium: This is the most important barrier. It consists of a single-cell 
layer of thick columnar cells in the airways, and thin and broad cells in the 
alveoli. 
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4. Interstitium and basement membrane: The interstitium is the extracellular 
space inside tissues. The epithelial and endothelial cells are attached to a 
tough but thin layer of fibrous material known as the basement 
membrane. Its role in macromolecule absorption is not known exactly.  
5. Vascular endothelium: The final barrier to systemic absorption is a 
monolayer of cells that construct the walls of small blood vessels and 
 
Figure 2. (a) Characteristic dimensions of the airway tree [13] and (b) Epithelial cell 
size and surface fluid thickness in different regions [16]. 
 
(a) 
(b) 
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lymphatics. Even at the tightest junctions, the vascular endothelium 
exhibits higher permeability to macromolecules than the epithelium. 
2.1.1. Deposition and clearance of inhaled particles 
For efficient pulmonary drug delivery, the aerosol must deposit in the 
lower airways. Since the lungs are in direct contact with the atmosphere, 
different defense lines protect the deep lungs from exposure to particles present 
in the inhaled air. There are several mechanisms in the upper respiratory tract 
that remove particles and reduce deposition in the lower airways. These 
mechanisms include impaction, sedimentation and diffusion (related to 
Brownian motion) [17, 18]. Small particles of diameters below 1 μm remain 
suspended in the air and are exhaled. A small fraction of them reaches the deep 
lungs and deposit due to Brownian motion. Particles with diameters larger than 
5 μm deposit in the upper respiratory system (mouth, throat and 
tracheobronchial airways) due to inertial impaction. Insoluble particles are 
cleared rapidly by cilia within the mucus layer lining the epithelium, which carry 
particles to the pharynx where they are swallowed, whereas soluble particles are 
removed via the lymphatic system. Particles with diameters of 1-5 μm deposit in 
the deep lungs due to a combination of inertial impaction and sedimentation. 
Scavenging cells (primarily macrophages) engulf and clear these particles either 
by the mucociliary elevator or the lymphatic system. 
 11 
Deposition in the respiratory tract is affected by the aerosol’s particle size, 
the patient’s inhalation technique and health, and the aerosol delivery system 
[19]. The most important formulation variable for respiratory drug delivery is the 
aerodynamic diameter (Daer) of the particles. The mass mean aerodynamic 
diameter (MMAD) for non-porous particles is defined by: 
D
ρ
ρ
MMAD
1
⋅=  
where, D is the mass mean geometrical diameter of the particle, ρ is the 
mean particle mass density, and ρl = 1 g/cm3 (density of water). The MMAD of 
the particle corresponds to the diameter of a sphere of ρ = 1 g/cm3 were it to fall 
under gravity with the same velocity as the particle in question. It is possible to 
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Figure 3.    Deposition/clearance fate of inhaled particles in/from the deep lung  
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generalize the above equation for highly porous particles. Experiments show this 
optimal aerodynamic diameter to be in the range of 1-5 μm [17]. However, the 
highly active pulmonary macrophage system is optimized to clear these particles 
arriving at the deep lung. The majority of crystallized pharmaceutical powders 
with specific gravity close to 1 and aerodynamic diameters in the respirable 
range are subject to rapid macrophage uptake, clearance, and removal. The 
expected lifetime of particles in the 1-5 µm range in the lung is therefore less than 
1 hr. Figure 3 summarizes the defense mechanisms of the lungs in order to 
quickly and effectively remove inhaled particles. 
A breakthrough discovery came in the mid 1990s, when Edwards et al. [6] 
recognized that the macrophage uptake system relied on the geometric diameter 
of particles to recognize and clear them, while the deposition of the particles in 
the lung depended on the aerodynamic diameter. They demonstrated that by 
preparing particles with very low specific gravity (<0.1), aerodynamic diameters 
in the respirable range (1-5 μm) could be achieved with geometric diameters in 
the 30 µm range. These geometrically large particles were too large for 
macrophage uptake and therefore provided long residence time in the lung. 
Controlled release of insulin over several days was demonstrated by this 
technique. This technology (called AIR®) has led to clinical development of an 
inhaled insulin formulation by Alkermes and Eli Lilly Company. 
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2.2. Agglomerated Vesicle Technology (AVT) 
In an attempt to bring post-inhalation modulation of drug release rate, our 
group has recently proposed a microparticle agglomerate of nano-sized 
liposomal particles, with the agglomeration process consisting of chemical cross-
links that are capable of cleavage. This approach has been named as – the 
Agglomerated Vesicle Technology (AVT) since it is based on the controlled 
agglomeration of particles. The cleavage of the cross links releases internal 
 
Cross-Linking 
 Chemistry 
 
in-vivo cleavage 
+ 
(a) 
(b) 
(c) 
Figure 4.      Schematic of core particles bearing ligands (a); agglomeration of core 
particles by linkers to form agglomerates (b); based on the linker chemistry some can 
be cleaved in-vivo by components of lung fluid or addition of a second agent (c). 
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surface area, as well as possibly results in the disruption of the bilayer. The result 
is a rapid release of encapsulated drug upon contact of the agglomerates with the 
cleaving agent. The approach is illustrated in Figure 4. In this figure, core 
particles with spacer arms, bearing ligands on their ends are shown as the 
starting point. The core particles could be polymeric nanoparticles with drug 
incorporated into them, or even drug nanoparticles to which the spacer arms 
have been conjugated. A particularly versatile choice for core nanoparticles are 
liposomes, that can conveniently be fabricated to present a variety of ligands at 
the distal ends of spacer PEG chains [20]. The ligands at the distal ends of the 
spacer arms are then used to cross-link the nanoparticles into larger clusters or 
agglomerates, by using a suitable chemical reaction. For example, by choosing 
nanoparticles with –COOH and –NH2 ligands, one could cross-link them using 
the carbodiimide reaction [21]. Depending on the conditions of the reaction 
mixture, one would expect the resultant agglomerates to have different densities. 
For example, under diffusion-limited conditions, where the overall concentration 
of the core nanoparticles and linker are low, the so-called diffusion-limited-
aggregation condition would apply, resulting in a limiting fractal dimension of 
1.5-2.5 [22 - 25]. Depending on the particular conditions of the chosen reaction 
scheme, other fractal dimensions could be achieved. Most chemical reactions are 
expected to be rapid compared to the diffusion of relatively large (100 – 400 nm) 
liposomes, resulting in DLA (diffusion limited agglomerate) clusters being 
formed. 
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Zasadzinski has shown that colloidal aggregation can be made self-
limiting by controlling the ratio of the reactive groups on the colloidal surface to 
cross-linking agents [26]. According to that study, unilamellar vesicles (0.1 μm) 
incorporating a small fraction of receptors formed aggregates via ligand-receptor 
interactions. The aggregates had dramatically different sizes depending on the 
ratio of receptors to cross-linking agents. However, the streptavidin-biotin based 
linkage is likely to be immunogenic and therefore is not acceptable for clinical 
use. 
The choice of the linker can impart other interesting properties to the 
agglomerates. For example, EGS [ethylene glycobis(succinimidylsuccinate)] links 
amino groups with each other, via an ester linkage [21]. The ester bond can be 
readily hydrolyzed with hydroxylamine, resulting in breakage of a link between 
the core nanoparticles. If an aggregate were built using the EGS linker, one 
would expect cleavage of the links to slowly result in release of the core 
nanoparticles. Assuming that the nanoparticles release drug much faster than the 
agglomerates, one would therefore expect a progressive increase in drug release 
rate as the hydrolysis of linkers proceeded. Similarly, if one were to cross-link 
particles using a dithiobenzyl (DTB) urethane linkage [27], the linker would 
carry a disulfide bond that would be cleaved by the addition of free thiols. While 
there are low levels of cysteine and glutathione in the lung, capable of causing 
some cleavage of disulfide links between nanoparticles, the further addition of a 
free thiol as a “cleaver” dose would trigger the accelerated release of drug by 
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cleavage of the inter-particle links and liberation of the free nanoparticles. A non-
biocompatible cleaver can be used as an in-vitro tool to investigate the release 
profile.  
Other very interesting structures are also conceivable, for example initial 
agglomeration by a non-cleavable linker, followed by agglomeration with a 
cleavable linker, or initial agglomeration by a cleavable linker followed by 
additional agglomeration by a non-cleavable linker. Inducing cleavage in such a 
structure would result in other triggered release patterns that could potentially 
be therapeutically useful. 
 
2.2.1. Agglomeration methodology of liposomes 
While one could conceive of any nanoparticle presenting an appropriate 
ligand on the external surface as a candidate for this technology, we have 
focused on the use of liposomes. Liposomes have several advantages for use as 
the core nanoparticles: (1) they can easily be produced in a range of sizes, (2) they 
can efficiently be loaded with a variety of drugs, (3) they can easily incorporate 
polymer spacers on their exterior surfaces by anchoring the spacer to a lipid 
molecule that in turn resides in the bilayer wall, (4) the bilayer wall composition 
can be manipulated to achieve a range of drug release properties, and (5) many 
lipids, including the ones chosen for liposome preparation are already 
abundantly present in lung surfactant and lung fluids, and would therefore be 
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Figure 5. a) A unilamellar liposome; and b) details of the lipid bilayer. 
well tolerated by the lung, making high excipient loads quite acceptable. One 
would have to consider the toxicity of the lipid-polymer conjugate used to 
provide the inter-particle spacers, but that problem appears small compared to a 
situation where the entire particle is composed of a polymer that has toxicity 
issues. In this work therefore, liposomes were chosen that consisted of 55-58% 
DPPC bilayer, with 40% Cholesterol and 2-5% DSPE-PEG-NH2. 
Liposomes, or lipid vesicles, are self-assembled colloidal particles (figure 
5) that occur naturally and can be prepared artificially, as shown by Bangham in 
the mid-1960s [28, 29, 30]. Initially, liposomes served as a case to study biological 
membranes and later in the 1970s they were considered candidates for drug 
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delivery. Presently, liposomes are the leading nanoparticles used in drug 
delivery with several products based on them. These products range from drug-
dosage forms (antifungals, anticancer agents, vaccines) and cosmetic 
formulations (skin-care products, shampoos) to diagnostics and various uses in 
the food industry.  
The benefits associated with the encapsulation of drugs in these carriers 
were mainly two-fold: (1) protection of the drug from chemical or metabolic 
degradation after administration, and (2) reduced toxicity through decreased 
exposure of the drug to healthy tissues. In general, these preparations exhibited 
significant reduced toxicity in comparison to the same drug administered by the 
conventional, unencapsulated form. A classic example is that of the antifungal 
drug, Amphotericin B, which reacts with all cells resulting in high toxicity. Also 
the peculiar solubility issues of the drug make it an ideal candidate for liposome 
encapsulation. Early studies in laboratory animals using liposomes containing 
Amphotericin B showed an increased therapeutic index [30]. 
A further reason for selecting liposomes as the parent nanoparticles in the 
agglomerated particle technology is the wealth of literature on the use of 
liposomes for respiratory drug delivery. Liposomes have long been considered 
as respiratory drug carriers in aqueous nebulizer-based formulations. A concern 
with such use, of course, is the disruption of liposomes by the high shear forces 
experienced by the fluid in the nebulization process. However, there have been 
studies [31] examining the effects of nebulization by different nebulizers on the 
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encapsulation of drugs by liposomes. Based on this, one would then be able to 
select a nebulizer that minimizes the disruption of liposomes, and the resultant 
loss of encapsulation. Liposomes have also been considered as candidates for dry 
powder inhalation. While liposomes are in general not stable upon drying (the 
existence of the bilayer depends on the free energy reduction achieved by the 
assembly of the amphipathic molecules in aqueous medium) there have been 
numerous examples of the drying of liposomes after protecting the bilayer with a 
suitable sugar such as trehalose [32]. Liposomes and even simple lipids have also 
been shown to promote trans-alveolar permeation of drugs. For example, it has 
been shown by Mitra et al. [33] that the mere presence of lipids co-administered 
to the lung along with insulin increased the bioavailability of insulin by 40%. 
Similar enhancements have also been reported by the same group for liposomes 
containing insulin. It therefore appears that liposomes are a good choice for core 
nanoparticles. 
 
2.2.1.1. Preparation of liposomes 
Factors that influence the hydration of the lipids and the vesicle formation 
process are the size of the raw lipid material, the hydration temperature and the 
bilayer phase transition temperature, shear forces, composition of the hydration 
medium and time [30]. Vesicle formation is greatly accelerated when the 
hydrated lipids are in the liquid crystalline state above their main transition 
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temperature (Tm). The vesicles formed are predominantly multilamellar vesicles 
(MLVs). When a drug is dispersed with the dry phospholipids or in the 
hydration buffer, encapsulation will occur during the vesicle formation.  
 The hydration of the lipids using organic solvents is achieved by injecting 
an organic solution containing the lipids, which is miscible with water (e.g. 
ethanol), into an aqueous phase. The resulting dilution of the organic solvent 
induces MLV vesicle formation. An attractive sizing technique to obtain small, 
unilamellar vesicles is low-pressure extrusion of the liposomal suspension under 
moderate pressures (<1 MPa) through polycarbonate membranes with well-
defined pore diameters. Polycarbonate filters with pore sizes ranging from 0.8 
down to 0.03 μm are available. The resulting vesicle size and lamellarity are 
related with the pore size, although effects of the medium and phospholipid 
composition are generally observed as well. Extrusion rates depend on the 
bilayer phase. The highest rates are obtained with phospholipids heated above 
the Tm, even when cholesterol is present, which abolishes the transition from the 
gel to the liquid crystalline state. The possible effects of the phospholipid 
composition on the obtained vesicle size can be minimized by repeated extrusion 
cycles. 
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2.2.1.2. Encapsulating drugs within liposomes 
Drugs can be encapsulated within liposomes by two different ways: (1) 
passive encapsulation, where the drug is entrapped within the liposomes during 
the vesicle formation process, and (2) active or remote loading, where the drug is 
loaded into preformed vesicles. 
Passive encapsulation is suitable for water soluble compounds that do not 
interact with the bilayer. The encapsulation efficiency directly depends on the 
aqueous volume enclosed by the vesicles, which itself depends on the 
phospholipid composition of the dispersion and the lamellarity and morphology 
of the vesicles. The encapsulation capacity but not the efficiency can be improved 
by using a high drug concentration (limited by solubility) during the vesicle 
formation process. The physical dimensions of lipid molecules and their 
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Figure 6.  Dependence of the amount of encapsulated insulin to size of liposomes 
passively encapsulating insulin from a pool concentration of 30 mg/mL. 
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contribution to the encapsulation efficiency of liposomes has been described by 
Lasic [30].  
Using insulin as an example, figure 6 shows the portion of a 30 mg/mL 
pool insulin concentration loaded passively into liposomes as a function of 
liposome size, and lipid concentration. Assuming a bioavailability of 25% of 
inhaled insulin [5] and a daily dose of insulin for an adult Type-I diabetic patient 
of 50 IU (1 mg≈27.6 IU), one can readily see that, in the case of 250 nm 
liposomes with 75 mM lipid content and 30 mg/mL insulin pool concentration, 
about 0.650 ml of suspension and 35 mg of lipid will be needed to carry the 
insulin required. While with a polymeric excipient, this load may be 
unacceptable, with a lipid excipient, one can easily justify this drug:excipient 
ratio, since the lipids used are already present in the lung in larger quantities 
than administered with this formulation. 
The remote loading depends on a proton gradient along the liposomal 
bilayer. Partition coefficients of drugs can depend on the pH, and to a lesser 
extent on the ionic strength of the aqueous medium [28]. 100% of the drug can be 
effectively encapsulated within liposomes depending on the conditions selected. 
The earliest drugs characterized for active loading were lipophilic cations or 
anions [34]. It has been shown by a number of groups [35 – 37] that a zwitterionic 
drug like Ciprofloxacin can also be actively loaded using an ammonium sulfate 
ion gradient method. Ciprofloxacin possesses both an amino and a carboxyl 
functional group. At a pH < 6 it has a net positive charge, whereas above pH 9 it 
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has a net negative charge. Below or above these pH extremes, Ciprofloxacin is 
highly soluble in aqueous media, however at physiological pH values it is 
practically insoluble. In general, a charged species cannot cross the bilayer at a 
significant rate; consequently it is the uncharged species that is able to diffuse 
into the vesicle down its concentration gradient.  
In a two chamber aqueous system separated by a membrane as illustrated 
in figure 7 using doxorubicin as an example, accumulation will occur at the low 
pH side under dynamic equilibrium conditions. A transmembrane pH-gradient 
causes accumulation of doxorubicin (pKa=8.1) in the low pH interior. In the 
unprotonated form, doxorubicin can diffuse through the bilayer. At the low pH-
side the molecules are predominantly protonated, which lowers the 
concentration of this drug in the unprotonated form, and thus promotes the 
diffusion of doxorubicin to the low-pH side of the bilayer from the external side. 
            
 
         INSIDE                                                       OUTSIDE 
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Figure 7. Schematic representation of the active loading technique.  
liposomal wall 
 24 
 
2.2.1.3. Tether selection for agglomeration 
The density and porosity of the agglomerates are clearly a function of the 
spacer length chosen and the size of the starting particles. Further, the more rigid 
this spacer is, the more rigid the agglomerate will be. However, a rigid, non-
flexible spacer would limit the efficiency of agglomerate formation since the 
terminal ligands, constituting the reactive groups that help the nanoparticles 
agglomerate, would not be free to move in all directions and seek other reactive 
groups during the reaction step. The reaction rate would therefore be limited by 
the diffusion of the relatively large, slow moving liposomes. It is not clear at this 
time, what the ideal choice of spacer for any given application would be, and the 
effect of different tethers is a topic of ongoing investigation. In the present work, 
polyethylene-glycol (PEG) tethers were chosen since: (1) they are readily 
available conjugated to lipids and (2) much is known about the safety of PEG-
lipids.  
2.2.1.4. Agglomeration chemistries 
Cross-linking chemistries are well known in bioconjugation of proteins 
and other molecules [21]. These techniques have been utilized to couple particles 
together. In earlier studies carbodiimide, NHS ester, and imidoester linkers have 
been used for agglomerating both polymer particles and liposomes [38]. 
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In this work the following imidoester and NHS linker chemistries have 
been investigated for cross-linking liposomes: 
a) DTBP (dimethyl 3,3’-dithiobispropionimidate•2HCl) is a 
homobifunctional imidoester that reacts with primary amines to form stable 
Figure 8. Reaction scheme for DTBP agglomeration [21] followed by cleavage with DTT. 
covalent bonds. In mildly alkaline pH’s (7-10), DTBP reacts with amine-
containing molecules forming charged amidine bonds. The disulfide bond on the 
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linked conjugate can be cleaved with a strong thiol like DTT (Dithiothreitol) at 37 
0C. The reaction scheme for DTBP is illustrated in figure 8. 
b) DTSSP (Dithiobis[succinimidylpropionate]) is a water-soluble, 
homobifunctional N-hydroxysuccinimide (NHS) ester. This cross-linker is active 
towards the primary amines resulting in a covalent amide bond and the release 
of N-hydroxysuccinimide. The reaction scheme is illustrated below in figure 9. 
This is also a thiol cleavable linker well known to be cleavable by DTT.  
Figure 9. Agglomeration scheme for DTSSP agglomeration [21]. 
It was found that this linker is also cleavable by a mild thiol like cysteine, 
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as witnessed by the size reduction of agglomerates made with DTSSP on 
incubation with cysteine.  
 
2.2.2. Triggered release of drug 
With the goal of ‘in vivo’ post-inhalation modulation of drug release rate, 
a DTB-urethane conjugate cleavable by an ‘in vivo’ acceptable compound such as 
cysteine [27] was developed in our lab. In vitro results showing release and size 
reduction was demonstrated [8]. However, with the finding that DTSSP, a 
commercially available cross-linker, is cleavable by cysteine, and also the limited 
success with the synthesis of a clean DTB-urethane conjugate in considerable 
quantities for the studies to be undertaken, the triggered release studies in 
animals were done based solely on the DTSSP linkage with no DTB coupled to 
the PEG-lipid. 
 
2.2.2.1. Using  cysteine as a trigger 
In order for cysteine to act effectively as a cleaving agent to the AVT 
particle, the required concentration of cysteine in the lung surfactant should be 
below 300 mM representing a total amount of about 1 gram. L-cysteine and its 
derivative N-acetyl-L-cysteine (NAC) are available as commercial dietary 
supplements from numerous manufacturers. Cysteine is an amino acid which is 
commonly found in food and synthesized by the body. NAC helps break down 
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mucus (for that reason, inhaled NAC is used in hospitals to treat bronchitis), 
increase levels of the antioxidant glutathione, and detoxify harmful substances in 
the body. Mucomyst® brand of acetyl-cysteine (Bristol Laboratories), a mucolytic 
agent for inhalation, requires a maintenance dose of 6 grams for an adult with a 
body weight of 80 kg. Hence, the needed dose of cysteine as a cleaving agent is 
not considered forbidden for ‘in vivo’ use at this preliminary stage of this work. 
 
Chapter 3 
Methods and Experimental Procedures 
3.1. Analytical Methods 
The methods and techniques that were used in the study for 
characterizing the particles and assaying the drug are discussed briefly here. 
 
3.1.1. Dynamic Light Scattering 
The parent liposomes that were fabricated and used in the study were in 
the submicron range. For measuring such small particles, Dynamic Light 
Scattering (DLS) is a very popular and useful technique [39]. Light incident on 
particles in solution is scattered in all directions. The light scattered by different 
particles is of different phase. The DLS technique is dependent on the molecular 
diffusion rate, and monitors the time-dependence of intensity of light scattered 
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from the particles. The rate at which the intensity fluctuates about its average 
value is dependent on the rate at which the molecules move in solution. The 
timescale on which the intensity domain fluctuation takes place is approximately 
equal to the time required by two molecules to diffuse far enough relative to each 
other such that the phase difference between the two, changes from zero to pi 
radians. The intensity domain output is transformed into a time domain output 
by autocorrelation. The measured autocorrelation function G(τ) is given as  
G(τ) = A[1 + B | g(τ) |2]  … (3.1) 
where, 
A → baseline value, 
B → machine constant, 
g(τ) → normalized first-order autocorrelation function. 
For a monodisperse system of particles g(τ) becomes a simple exponential 
decay, and equation (3.1) is transformed to:  
 
G(τ) = A[1 + B exp(-2Dq2τ)]  … (3.2) 
where, 
D → coefficient of diffusion, 
q → scattering vector [q = (4pi/λ)sin(θ/2)], 
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λ→ wavelength of laser in air, 
θ → angle of scatter, 
τ → time. 
For a Newtonian fluid and spherical particles, the diffusion coefficients 
are related to the hydrodynamic diameter of the particles by the Stokes-Einstein 
equation as, 
D = kBT/(3piηd)  … (3.3) 
where, 
kB → Boltzmann’s constant, 
T → absolute temperature in oK, 
η → viscosity of the liquid, 
d → particle diameter. 
The DLS measurements for this study were done on a Brookhaven 
Instruments BI-9000AT Digital Autocorrelator, a BI-200SM goniometer and a 
Hamamatsu photomultiplier (Brookhaven Instruments Corp., Holtsville, NY, 
USA). The light source was a 532 nm, Ti-sapphire, frequency doubled laser. For 
the DLS measurement, the liposomal suspensions were appropriately diluted in 
the buffer used to prepare the liposomes. 
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3.1.2. Fraunhofer Diffraction Pattern Analysis 
Fraunhofer diffraction is widely used for characterizing particles in the 1-
200 µm size range [40, 41]. The sample is normally a liquid or gas suspension of 
particles whose size distribution is to be determined. Laser energy from the 
source is scattered by the particles, resulting in a characteristic energy 
distribution at small angles of deviation from the forward beam. A portion of this 
scattered pattern is focused onto a detector by a lens of known focal length. A 
schematic of a typical Fraunhofer diffraction experiment is shown in figure 10. 
The detector response is averaged over a period of time and recorded. The size 
distributions are determined by numerically inverting the recorded pattern. For a 
monodisperse system of spherical particles in the sample which are larger than 
the wavelength of the light used, the diffraction pattern would be described by 
the characteristic Airy diffraction equation: 
 
Figure 10. Fraunhofer Diffraction Pattern Analysis system [41]. 
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I(θ) is the scattered intensity at any angle θ, λ the wavelength of the 
incident light, D the diameter of the particles in the sample, and n(D) the particle 
size (number) distribution. 
 This pattern is then refracted by a transform lens (of finite aperture) onto a 
detector of finite diameter. Neglecting the aberrations due to finite aperture, the 
transformed pattern can be obtained by the following transformation: 
θfr =   
Where, f is the focal length of the lens and r is the radial position of the 
pattern. 
The light energy within any detector ring on the focal plane bounded by 
radii s1, s2 due to a particle of radius r is given by: 
L s1,s2 = E{Jo2(krs1/f) + J12(krs1/f) – Jo2(krs2/f) – J12(krs2/f)} . . . (3.6) 
where, 
f → focal length, 
E → energy falling on the particle that is proportional to the cross 
sectional area of the particle, 
Jo, J1 → Bessel functions of the zeroth and first order respectively and first 
kind. 
. . . (3.4) 
. . . (3.5) 
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For a collection of particles of different sizes, the total energy is a sum over 
all the sizes and is given as: 
Ls1,s2 = C ∑
M
i
 Ni {(Jo2 + J12)s1 – (Jo2 + J12)s2}  . . . (3.7) 
where, 
C → proportionality constant, 
Ni → number of particles of a particular size. 
The detector response (normally a voltage or a current, depending on the 
energizing and analysis circuitry), which is proportional to the incident energy is 
then given by; 
Vs1,s2 = C’ .Ls1,s2    . . . (3.8) 
The size distribution can then be calculated from the detector response by 
using several methods. The two most popular methods used are the model-
dependent and the model-independent methods. The model dependent method 
assumes a model such as the Log-Normal or Rosin-Rammler for the size 
distribution. The utility of the model-dependent inversion technique is limited to 
unimodal distributions. The model-independent technique tackles the more 
general multimodal distributions which makes no such assumptions. However, 
the number of available detector channels also limits the number of size classes 
which can be included in the model-independent analyses. This is normally 32 
classes. 
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The Fraunhofer Diffraction Pattern Analysis method works very well for 
unimodal systems. For sharp-peaked multimodal systems, there is a strong 
tendency to skew the distribution towards the mode that contributes the 
strongest peak in the diffraction pattern. In the presence of small particles (<1 
μm, just below the lower limit of the FDPA system), the modes of multimodal 
distributions can be assigned incorrect mass fractions.  
It should be noted that the Fraunhofer theory is based on the ideal case of 
hypothetical particles. In reality, particles could be non-spherical, and possess 
refractive indices that are close to that of the medium. If the particles were 
multimodal with a mode larger than the upper limit on size, the measurement 
would be inaccurate. 
A Malvern Mastersizer (Malvern Instruments Inc., Southborough, MA, 
USA) with a 100 mm lens was used to do the FDPA on the agglomerated 
liposomes. 
 
3.1.3. Cascade impaction for aerodynamic characterization of aerosols 
Aerosol particles can be spherical or highly irregular in shape. Due to a 
variety of shapes, it is difficult to describe an aerosol particle by a single number 
like diameter. One way of describing the size of a particle is by the description of 
equivalent aerodynamic diameter. The aerodynamic diameter of a sphere can be 
equated to its geometric diameter by deriving from Stokes Law as, 
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ρDD geoaer ⋅=   
where, Daer is the aerodynamic diameter, Dgeo is the geometric diameter, and ρ is 
the specific gravity of the particle with respect to water. 
Cascade impactors have been widely used to characterize the 
aerodynamic size distribution of aerosol particles. The working principle 
involves the drawing of ambient air through the inlet port into a series of stages 
connected by successive smaller orifices. The number of stages is typically 6 to 7. 
As the aerosol particles flow through the stages of the device, they are propelled 
toward the collection plates on each stage with increasingly higher inertia. If the 
particle has sufficient inertia, it will impact the plate; else it will be carried by the 
air flow into the successive stage. Submicron particles that are not collected on 
the last collection plate are caught up in the backup filter, immediately 
downstream from the last stage. Once the sampling is complete, the amount 
deposited on each stage is determined. The measurement results in a size 
distribution of the aerosol particles. 
An Andersen Cascade Impactor, series 20-800, 1 ACFM non-viable 
sampler (Thermo Electron Corp., Waltham, MA, USA) was used to determine the 
aerodynamic diameters of the agglomerates. 
 
. . . (3.9) 
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3.1.4. Microscopy 
Microscopy is a widely used technique that produces visible images of 
structures or details that are too small to be seen by the eye, by using either a 
microscope or a magnification tool. 
In conventional microscopy, the resolution of the image depends on the 
wavelength of the incident radiation, which could be light, electron beam, or an 
X-ray. The lower wavelength of electron beam results in an image with higher 
resolution.  
The techniques discussed below were used to evaluate the morphology 
and size of the agglomerates: 
 
3.1.4.1. Confocal Laser Scanning Microscopy 
Confocal laser scanning microscopy (CLSM) is a valuable tool for 
obtaining high resolution images and 3-D reconstructions. The key feature of 
confocal microscopy is its ability to produce blur-free images of thick specimens 
at various depths. Images are taken point-by-point and reconstructed with a 
computer, rather than projected through an eyepiece. 
In a laser scanning confocal microscope, a laser beam passes a light source 
aperture and is then focused by an objective lens into a small (ideally diffraction-
limited) focal volume within a fluorescent specimen. A mixture of emitted 
fluorescent light as well as reflected laser light from the illuminated spot is then 
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recollected by the objective lens. A beam splitter separates the light mixture by 
allowing only the laser light to pass through and reflecting the fluorescent light 
into the detection apparatus. After passing a pinhole, the fluorescent light is 
detected by a photo-detection device [photomultiplier tube (PMT)] transforming 
the light signal into an electrical one which is recorded by a computer 
 
 
Figure 11. Working principle of confocal microscopy. 
 
The agglomerates (encapsulating carboxyfluorescein dye) in this study 
were imaged with a Zeiss LSM 510 META confocal microscope using a ×63 
immersion oil objective (Carl Zeiss, Germany). 
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3.1.4.2. Negative Staining Electron Microscopy 
Electron microscopes were developed to overcome the limitations of light 
microscopes, which are limited by the physics of light to 1000X magnification 
and a resolution of 0.2 µm. They are able to achieve 10,000X plus magnifications 
that are just not possible using light microscopes. By achieving these 
magnifications, finer details of a specimen can be observed with a resolution in 
the nanoscale length limits. 
An electron microscope uses a highly energetic beam of electrons that is 
focused on a specimen to examine objects on a very fine scale. The examination 
can yield information on; (1) the surface features of the object (topography), (2) 
shape and size of the particles that make up the object (morphology), (3) the 
elements and compounds that make up the object (composition), and (4) the 
crystallographic information of the specimen. 
Most biological materials show little contrast with their surroundings 
unless they are stained. In the case of light microscopy, contrast can be enhanced 
by using colored stains which selectively absorb certain wavelengths. The 
electrons in the electron microscope are absorbed very little by biological 
material and contrast is obtained mainly by electron scattering.  
To heighten the contrast between the specimen and the background, 
electron-dense "stains" are used. These are usually compounds of heavy metals 
of high atomic number (for e.g. uranium salts), that serve to scatter the electrons 
from regions covered with the stain. If particles are coated with stain (positive 
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staining), fine details may be obscured. Negative staining overcomes this 
problem by staining the background and leaving the particle relatively 
untouched. The negative stain is molded round the particle, outlining its 
structure, and is also able to penetrate between small surface projections and to 
delineate them.  
In this study, negative stained electron micrographs of agglomerates and 
liposomes were taken with a JEOL JEM1230 electron microscope operating at 80 
kV and 56 µA beam current. 
 
3.1.5. HPLC assay 
Chromatography is a general technique that separates a mixture into its 
individual components in order to evaluate each component, free from 
interference, from the other components. Chromatography can be coupled with a 
detection system that would enable a characterization of each component. High 
performance liquid chromatography (HPLC) is one such method. It is used to 
analyze liquid samples or the liquid extract of a sample.  
The fundamental basis for HPLC consists of passing a sample (chemical 
mixture) in a high pressure solvent (the mobile phase) through a packed bed of 
adsorbents (the stationary phase). As the chemical entities pass through the 
column they interact between the two phases; mobile and stationary, at different 
rates. The difference in rates is primarily due to different polarities of the 
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components. The components that have the least amount of interaction with the 
stationary phase or the most amount of interaction with the mobile phase will 
exit the column faster. Repeated interactions along the length of the column 
result in a separation of the entities. Various mixtures of the chemicals can be 
analyzed by changing the polarities of the stationary phase and the mobile 
phase.  
The stationary phase is typically bonded to a support phase, usually 
consisting of porous beads. The pore sizes can be varied to control the elution 
rate of different species. Furthermore, the dimensions of the column can also be 
varied to enable further control over the separation. 
A change in the polarity of the mobile phase can significantly affect the 
efficiency of any HPLC separation. The mobile phase polarity is generally the 
opposite of the stationary phase. The rate at which the polarity is changed 
defines the "gradient." This gradient technique helps to further separate mixtures 
of variously polar components.  
As the components exit the column, they can be detected by various 
means. Refractive index, electrochemical, or ultraviolet-absorbance changes in 
the mobile phase can indicate the presence of a component. The amount of the 
particular component leaving the column will determine the intensity of the 
signal produced in the detector. The detector measures a signal peak as each 
component leaves the column. By comparing the time it takes for the peak to 
show up (the retention time) with the retention times for a mixture of known 
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compounds, the components of unknown sample mixtures can be identified. By 
measuring the signal intensity (response) and comparing it to the response of a 
known amount of that particular component, the amount of the component in 
the mixture can be determined. 
The HPLC system used in the studies for assaying Ciprofloxacin consisted 
of a Shimadzu SCL-10Avp liquid chromatograph, SPD-10Avp UV-Vis detector 
(278 nm) and SIL-10Advp auto-injector (Shimadzu Scientific Instruments, 
Columbia, MD, USA). The chromatographic conditions were as follows: 
Chromatography was carried out with a Waters Symmetry 5µ C18 column, 150 x 
4.6 mm (Waters Corp, Milford, MA, USA); The column temperature was 
maintained at 28°C and the flow rate was 1.0 mL per minute; The mobile phase 
was a mixture of 15% (v/v) acetonitrile and 85% (v/v) 25 mM sodium phosphate 
buffer at pH ~ 2.3. The sample injection volume was 20 µL. Ciprofloxacin eluted 
within 10 minutes, under these assay conditions. 
 
3.2. Experimental procedures of the 1st generation of AVT (in vivo 
non-cleavable) 
In this section preliminary experiments that were undertaken are 
described. The early studies were done with blank liposomes (no drug 
encapsulated). The focus of these studies was to see how different reaction 
conditions, such as the amount of reacting groups, and pH of the reaction, 
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affected the agglomeration of liposomes. Ciprofloxacin was used as a model 
drug to investigate in vitro release characteristics of the agglomerates in addition 
to the aerodynamic properties of the agglomerated vesicles. Finally the 
agglomerates of DTBP (in vivo non-cleavable) encapsulating Ciprofloxacin were 
evaluated for drug release properties in vivo, by instilling formulations in the 
lungs of normal rabbits.   
 
3.2.1. In vitro experiments with blank liposomes    
3.2.1.1. Materials 
1,2-Dipalmitoyl-sn-Glycero-3-Phosphatidylcholine (DPPC) was purchased 
from Genzyme Pharmaceuticals (Cambridge, MA, USA). Cholesterol was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  Distearoyl 
phosphoethanolamine [Amino (polyethylene glycol)] (DSPE-PEG-NH2) conjugate 
was purchased from Avanti Polar Lipids Inc (Alabaster, AL, USA). The cross-
linker DTBP was purchased from Pierce (Rockford, IL, USA). All the rest of the 
reagents were purchased from Fisher Scientific. 
 
3.2.1.2. Fabrication and characterization of liposomes 
The liposomes were made by extruding a suspension of dissolved 
hydrated lipids through a single 400 nm Whatman Nuclepore polycarbonate 
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trach-etch membrane in a Lipex Biomembranes extruder (Vancouver, British 
Columbia, Canada). A lipid composition of 57-58% DPPC, 40% Cholesterol, and 
2-3% DSPE-PEG-NH2 conjugate was used. The lipids were dissolved in ethanol 
at 50-600 C and then hydrated with sodium citrate buffer (ethanol volume not 
exceeding more than 10% of the final volume), the lipid concentration in the final 
mixture being 50-100 mM. The suspension was then passed 7-10 times through 
the extruder at 50-540C and a pressure of approximately 100 psi. 
Assuming 51% of the DSPE-PEG-NH2 to be on the outer leaflet of the 
bilayer, the number of amine groups available for coupling with the cross-linker 
were estimated to be 0.26 x 10-6 moles/ml (10 mM lipid), 0.51 x 10-6 moles/ml (20 
mM lipid), and 1.28 x 10-6 moles/ml (50 mM lipid). The liposomes were 
characterized by Dynamic Light Scattering (DLS). 
3.2.1.3. Fabrication and characterization of agglomerates  
Liposomes were agglomerated using DTBP. Liposomes at a lipid molarity 
of 10, 20, and 50 mM were used for the agglomeration. The amount of DTBP 
used in the reactions were 25, 50, and 100 fold molar excess over the number of 
PEG-NH2 groups on the outer leaflet of the liposomes. The pH of the liposomes 
was monitored and maintained at ~8.15 (the optimal pH for DTBP activity is in 
the 8-9 range) with NaOH solution, and the linker was added to the liposomes 
with constant stirring for over 3 hours. The reaction was carried at room 
temperature. 
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To investigate the extent of the agglomeration process at various time 
points, aliquots of the reaction mixtures were taken and added to a buffered 
solution of 300 mM Tris. Tris is used as a quencher to arrest the reaction of the 
imidoester - DTBP, by providing free primary amines to the cross-linker.  
The sizes of the agglomerates were determined by the Fraunhofer 
diffraction technique.  
 
3.2.2. In vitro studies with Ciprofloxacin loaded liposomes 
3.2.2.1. Materials 
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA, 
USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).  
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc 
(Alabaster, AL, USA). The cross-linker DTBP was purchased from Pierce 
(Rockford, IL, USA). Ciprofloxacin (Bayer Pharmaceutical Corp, West Haven, 
CT, USA) was purchased from a local pharmacy as Cipro-I.V. solution and 
purified as follows: The pH of Cipro-I.V. solution was raised from 2.1 to 7 with 
sodium hydroxide to precipitate the Ciprofloxacin. The suspension was then 
centrifuged at 1500 x g (4000 rpm) for 10 minutes, and the supernatant discarded. 
The powder was then washed with DI water and centrifuged 4 times to remove 
lactic acid (an inert excipient in the i.v. solution). A final wash and centrifugation 
with ethanol yielded a wet powder which was collected and dried in a vacuum 
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desiccator. Ciprofloxacin yield was 90%. Survanta® was purchased from Abbot 
Laboratories (Abbott Park, Illinois, USA). All the rest of the reagents were 
purchased from Fisher Scientific (Hampton, NH, USA). 
3.2.2.2. Fabrication and characterization of liposomes 
The liposomes were made by extruding a suspension of dissolved 
hydrated lipids through a single 400 nm Whatman Nuclepore polycarbonate 
trach-etch membrane in a Lipex Biomembranes Extruder. A lipid composition of 
55% DPPC, 40% Cholesterol, and 5% DSPE-PEG-NH2 conjugate was used. The 
lipids were dissolved in ethanol at 50-600 C and then hydrated with 300 mM 
ammonium sulfate solution (ethanol volume not exceeding more than 10% of the 
final volume), the lipid concentration in the final mixture being 75 mM. The 
suspension was then extruded 7 times at 50-600C and a pressure of 
approximately 100 psi. 
Assuming 51% of the DSPE-PEG-NH2 to be on the outer leaflet of the 
bilayer, the number of amine groups available for coupling was estimated to be 
1.92 x 10-6 moles/ml (75 mM lipid). The liposomes were characterized by DLS. 
 
3.2.2.3. Loading of liposomes with ciprofloxacin 
Ciprofloxacin was loaded into liposomes of 75 mM lipid content by the 
ammonium sulfate gradient method [36]. Blank liposomes were prepared in a 
300 mM ammonium sulfate solution. 10 mL of the liposomes were dialyzed 
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(using 100,000 MWCO dialysis tubing) for 4 hours against 300 mL of saline at pH 
of 5.2 (adjusted by HCl) in order to remove ethanol and ammonium sulfate from 
the external phase of the liposomes and to establish the proton/sulfate gradient. 
Ciprofloxacin was dissolved in saline at pH 4.2 and 52ºC. The solution of 
Ciprofloxacin (15 mL) was added gradually to the liposomal suspension (15 mL) 
and the temperature was maintained at 52ºC. The remote loading procedure was 
terminated after 1 hour by rapidly dropping the temperature using an ice bath. 
The drop in temperature reduces the permeability of the liposome bilayer thus 
preventing the transfer of species across the bilayer and entrapping the loaded 
drug. Finally, the liposomal suspension was dialyzed for 4 hours against 300 mL 
of saline at pH 5.2 to remove unencapsulated Ciprofloxacin. The final lipid 
content of the Ciprofloxacin-loaded liposomes was 37.5 mM. 
Dialysis (using 100,000 Dalton MWCO tubing) was used to evaluate the 
encapsulated fraction of drug. The Ciprofloxacin-loaded formulations were 
dialyzed against saline at pH 5.2. The volume of the external buffer was 100 
times the volume of the liposomal formulation. Samples were taken from the 
external phase and were assayed. Complete removal of the unencapsulated drug 
was considered to be achieved, when the external phase concentration remained 
unchanged for 6 hours. Then, the formulation was removed from the dialysis 
tubing, lysed with methanol (30% of total volume), and assayed by HPLC to 
measure the encapsulated amount of drug. 
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3.2.2.4. Agglomeration and characterization of Ciprofloxacin-loaded 
liposomes  
Liposomes were agglomerated using DTBP. The coupling reaction of the 
PEG-amines with DTBP was carried out in pH of 5.2 (same pH as for 
Ciprofloxacin loading) or 8.5 (optimal pH for linker activity) in saline. This was 
done to determine the pH that would be best suited for the agglomeration and at 
the same time would not result in drug leakage. The amount of DTBP used was 
100-fold molar excess of the NH2 groups on the PEG. 
The cleavage of the DTBP agglomerates was accomplished with 
dithiothreitol (DTT) at 37 0C. The sizes of the agglomerates were determined by 
the Fraunhofer diffraction technique. 
  
3.2.2.5. Aerodynamic properties of agglomerates 
The aerodynamic properties of the agglomerated liposomes containing 
Ciprofloxacin were evaluated by nebulizing 2 ml of the formulation into an 
Andersen Cascade Impactor (Series 20-800, 1 ACFM non-viable sampler). A 
Parijet LC nebulizer was used for the cascade impactor study. The impactor was 
operated under ambient conditions (24 ± 1 0C and ~ 55% relative humidity) at 
constant flow rate of 28.3 L/min (calibrated by the supplier). The vacuum pump 
connected to the impactor was started and the sample was nebulized into the 
cascade impactor for 15 minutes, sufficient to nebulize the entire contents. Finlay 
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et al. have emphasized the problems of droplet undersizing [42, 43] in a cascade 
impactor run at ambient conditions, due to heating of the nebulized air. They 
demonstrate mass mean aerodynamic diameters (MMADs) under ambient 
conditions to be 1 µm lower than under saturated air conditions. However, it is 
also known that that this shrinkage will be less in a larger droplet due to the 
lower surface area/unit volume. We have therefore operated the nebulizer and 
cascade impactor at ambient conditions, which is consistent with the USP 
method (USP 23, NF 18, <610>, 1995). 
At the end of the nebulization run, each plate of the impactor, the elbow 
piece, and the filter paper at the end of the last stage were washed several times 
with 10 ml of saline at pH ~ 5.2. Methanol (30% of total wash buffer by volume) 
was used to lyse the liposomes collected on each stage.  These washes were then 
analyzed by HPLC to determine the amount of Ciprofloxacin collected on each 
stage. The amount of Ciprofloxacin on each stage was then assigned to the 
corresponding aerodynamic diameter of each stage to determine the 
aerodynamic size distribution.  
The weight of the nebulizer containing the formulation was recorded 
prior to and at the end of the nebulization in order to estimate the amount of 
formulation nebulized into the cascade impactor. It was estimated that more than 
95% of the initial charge was nebulized. 
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3.2.2.6. Stability upon nebulization 
The effects of nebulization on the size and encapsulation of Ciprofloxacin 
were investigated. For this, the core liposomes and agglomerated formulations 
were nebulized, using a Parijet LC nebulizer, for a specific time into a conical 
flask, (figure 12) which contained 30 mL of saline. The secondary aim of this 
experiment was also to determine if the nebulizer was able to deliver the 
agglomerates.  
The nebulizer loaded with the formulation was weighed before and after 
every nebulization. After every nebulization, the device was weighed and a 
sample was taken for HPLC analysis of Ciprofloxacin content. This was used to 
determine the total amount of formulation nebulized into the flask. At the end of 
the experiment, the amount of Ciprofloxacin in the collected nebulisate was 
analyzed by HPLC. This was done to estimate the fraction of nebulized material 
collected in saline. 
 
 
 
 
 
 
Figure 12. Schematic for collecting nebulized formulations of liposomes and 
agglomerates for evaluating effects upon nebulization. 
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The size of liposomes in the collected nebulisate was determined by DLS, 
and the size of the agglomerates in the collected nebulisate was analyzed by 
Fraunhofer diffraction. The loss of encapsulated Ciprofloxacin from the 
liposomes and agglomerates was evaluated by dialysis (as described previously) 
of the collected nebulisate. 
 
3.2.2.7. In vitro release studies 
The release of Ciprofloxacin from agglomerates and liposomes was 
evaluated in-vitro. The commercial pulmonary surfactant replacement Survanta® 
was used to simulate the lung environment. Ciprofloxacin-loaded 
liposomes/agglomerates and Survanta® (3:1 volumetric ratio respectively) were 
incubated at 37 °C in a dialysis bag (100,000 MWCO) immersed in PBS at a pH of 
7.4. The volume of the external phase was 25 times that of the internal phase. 
Samples from the external phase were taken and were assayed for Ciprofloxacin 
in the HPLC. At the end of the experiment the contents of the dialysis bag were 
also assayed for Ciprofloxacin content. 
 
3.2.3. In vivo studies of Ciprofloxacin loaded liposomes 
To evaluate the drug release properties of the agglomerates made with 
DTBP (in vivo non-cleavable) in vivo, formulations of liposomes and 
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agglomerates were instilled in the lungs of rabbits. The experimental procedures 
are noted below. 
 
3.2.3.1. Materials 
DPPC and methoxypoly (ethylene glycol) distearoylphosphatidyl 
ethanolamine (MPEG-DSPE) were purchased from Genzyme Pharmaceuticals 
(Cambridge, MA, USA). Cholesterol (CHOL) was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). DSPE-PEG-NH2 conjugate was purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). DTBP was purchased from Pierce (Rockford, 
IL, USA). Ciprofloxacin (Bayer Pharmaceutical Corp., West Haven, CT, USA) 
was purchased from a local pharmacy as Cipro-I.V. solution and was purified as 
described in section 3.2.2.1. All other reagents were purchased from Fisher 
Scientific (Hampton, NH, USA). 
 
3.2.3.2. Animals 
New Zealand White male rabbits (2.9 ± 0.5 kg) were purchased from 
Myrtle Rabbitry (Thompson Station, TN, USA). The use of animals for this study 
was approved by the Center for Laboratory Animal Medicine and Care 
(CLAMC) of UTHSC-Houston. Care and handling of the animals was in 
accordance with all policies of the United States Department of Agriculture 
(USDA) and U.S. Public Health Service (PHS). 
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3.2.3.3. Fabrication and characterization of liposomes 
Two separate batches of liposomes (~120 mM lipid content) were 
prepared. A lipid composition of DPPC:CHOL:DSPE-MPEG (57:40:3, mol%) 
(MPEG terminated, for studies with liposomes), and DPPC:CHOL:DSPE-PEG-
NH2 (57:40:3, mol%) (amino terminated, for making AVT) was used. The lipids 
were dissolved in ethanol at 550 C and then hydrated with a 400 mM ammonium 
sulfate solution (ethanol volume not exceeding more than 10% of the final 
volume). The liposomes were made by extruding the suspension of the hydrated 
dissolved lipids through a single 400 nm Whatman Nuclepore polycarbonate 
trach-etch membrane in a Lipex Biomembranes extruder (Vancouver, British 
Columbia, Canada). The suspension was then passed 7-10 times through the 
extruder at 50-54 0C and a pressure of approximately 100 psi. The liposomes 
were characterized by DLS. 
 
3.2.3.4. Loading of liposomes with Ciprofloxacin 
Ciprofloxacin was loaded into liposomes by the ammonium sulfate 
gradient method [36]. Liposomes were diafiltered for 1-2 hours using 50 nm 
cutoff tubings with the external phase of the liposomes being replaced with 
saline (150 mM) at pH of ~5.3 in order to remove ethanol and non-encapsulated 
ammonium sulfate. For the remote loading procedure, Ciprofloxacin was 
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dissolved in saline (60 mg/ml) at pH 4.2 and 60ºC, and was gradually added (0.5 
ml added every 3-5 minutes) to the liposomal suspension with the temperature 
maintained at 60ºC. The loading was terminated after 1 hour by rapidly 
dropping the temperature using an ice bath. The drop in temperature reduces the 
permeability of the liposome bilayer thus preventing the transfer of species 
across the bilayer and entrapping the loaded drug. Finally, the suspension was 
separated from unencapsulated Ciprofloxacin by overnight dialysis against 
saline solution (100 times volume of liposomes) at pH 5.3. 
3.2.3.5. Agglomeration and characterization of Ciprofloxacin-loaded 
liposomes 
Liposomes containing 3% PEG-NH2 conjugate in the lipid bilayer were 
agglomerated using DTBP as the linker. The amount of DTBP used was a 50 fold 
molar excess over the number of PEG-NH2 groups on the outer leaflet of the 
liposomes. The pH of the liposomes was raised from 5.3 to 8.5 (the optimal pH 
for DTBP activity is in the 8-9 range) with NaOH solution, and the linker was 
added to the liposomes with constant stirring for 1.5 hours after which the pH 
was dropped to 5.3 to arrest the cross-linking reaction.  
The sizes of the agglomerates were determined by the Fraunhofer 
diffraction technique.  
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3.2.3.6. Pharmacokinetic study in rabbits 
Rabbits were anesthetized by a subcutaneous injection of 
ketamine/xylazine (40-50/5-10 mg/kg). The rabbits were maintained on 2% 
isoflurane and O2 (1 lit/minute). The heart rate, temperature and O2 were 
monitored periodically, and remained stable throughout the course of the 
experiment. 
The marginal ear vein was accessed via an i.v. catheter (24 G). The catheter 
was taped to the ear. Using a laryngoscope, an endotracheal tube (size 3) was 
inserted into the trachea, with a urinary catheter acting as a guide. Insertion into 
trachea was confirmed with a stethoscope, by pumping air into the lungs. The 
cuff of the endotracheal tube was filled with air to maintain the tube in the 
trachea. Additionally, the tube was tied to the mouth to retain it in place. 
The rabbit’s head was maintained in an upright position and drug 
formulation was instilled into the lungs with a syringe. The formulation was 
pushed down by forcing air into the lungs with the syringe several times. 2.2 to 
2.8 ml of formulation (corresponding to Ciprofloxacin doses of 17 ± 1.6 mg/kg) 
was instilled. 
Blood was drawn from the ear vein before (time 0) and after instillation of 
drug formulation. Blood samples were centrifuged at 13,400 rpm for 15 minutes 
to separate the plasma from cell components. The plasma was then diluted 1:4 
times with methanol: phosphate buffer (9:1 v/v) to precipitate the proteins 
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present in the sample. The resulting suspension was then centrifuged at 13,400 
rpm in a microcentrifuge for 15 minutes and the supernatant was assayed for 
Ciprofloxacin content by HPLC. Standard curve for Ciprofloxacin was 
determined by spiking known amounts of Ciprofloxacin in rabbit plasma. The 
lowest detection limit by HPLC was 0.05 µg/ml. 
The following formulations were instilled into the lungs: 
a) Free Ciprofloxacin solution. 
Ciprofloxacin was dissolved in normal saline at a concentration of 21.9 
mg/ml. The pH of the solution was adjusted to approximately 3.1 to maintain 
Ciprofloxacin in solution. This solution was then instilled into the lungs of the 
rabbits as described above.  
b) Liposome-encapsulated Ciprofloxacin 
The instillation of the Stealth® liposomes was as described by the 
procedure above. The final lipid content of the liposomes that were instilled was 
~110 mM. 
c) AVT1 
AVT particles made with the cross-linker DTBP that were used for the 
pharmacokinetic studies in rabbits are referred to as AVT1. These agglomerates 
are not susceptible to cysteine cleavage. They were instilled according to the 
procedure described above. The final lipid content of the AVT1 that was instilled 
was ~50 mM. 
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3.2.4. In silico study of Ciprofloxacin pharmacokinetics of the 1st 
generation AVT 
A deterministic compartmental model was employed to analyze the 
Ciprofloxacin profiles obtained from the pharmacokinetic studies. The model 
shown in Figure 13 consisted of 4 compartments with most of pharmacokinetics 
being assumed first order. In order to understand the pharmacological 
phenomena and the related physiological meaning, possible release mechanisms 
of Ciprofloxacin from the AVT particle were proposed by introducing the 
“particle” compartment.  
 
Figure 13. Sketch of the compartmental model. 
 
 
It was hypothesized that 2 mechanisms are important to describe the 
release from the liposomes and AVT particles:  
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1. Once the liposomes and agglomerate microparticles were instilled into the 
lungs of the rabbit, forces due to motion of the lungs caused a degree of 
fragmentation resulting in immediate release of a portion of the 
encapsulated drug. Therefore, the input amount into the “particle” 
compartment was the total load of Ciprofloxacin into the particle 
subtracted by “α” which is used to represent the amount leaked from the 
AVT particle due to fragmentation (equation 1). It is assumed that shear 
forces are experienced by the particle until the particle comfortably 
reorients itself. The reorientation was assumed to occur instantaneously 
upon deposition in the lungs.  
2. The second mechanism of release was attributed to a diffusion process 
represented with the first order rate constant kAVT in equation 2. The drug 
molecule is assumed to diffuse initially through the liposomal wall and 
then through the matrix of the agglomerate. 
Input Bolus=
AVTV
α-D
β =  
 
(1) 
 
D 
α 
VAVT 
initial dose of Ciprofloxacin (µg) 
amount of Ciprofloxacin leaked from particles due to disruption (µg) 
internal volume of the liposomes (ml) 
 
    Ck
dt
dC
AVTAVT
AVT
⋅−=  
 
(2) 
CAVT 
kAVT 
Ciprofloxacin concentration in the “particle” compartment (µg/ml) 
first order constant to the “lung” compartment (hr-1) 
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In the case of the liposomes, the subscripts with “AVT” are replaced with 
“Lips”. 
In the case of the “lung” compartment, the elimination rate could be 
attributed to (a) transport of the Ciprofloxacin molecule to the lymphatic 
circulation, and (b) macrophage uptake of liposomes, and agglomerates when 
their fragments fall into geometrical sizes (due to size decrease induced by 
rupture due to the motion of the lungs) within the macrophage uptake range. 
The total clearance is described via the first order elimination process (kL0). 
Besides the elimination rate and the flux towards the “blood” compartment (both 
first order), a bolus input (α) was introduced which represents the amount of 
drug that leaked from the AVT particles (or liposomes) during 
reorientation/fragmentation.  
 
Input Bolus=
LV
α
 (4) 
 
 
( ) LL0LAVTAVTL CkkCkdt
dC
⋅+−⋅=  
 
(5) 
VL 
CL 
kL0 
kL 
volume of the pulmonary surfactant (mL) 
Ciprofloxacin concentration in the “lung” compartment (µg/ml) 
first order elimination constant (hr-1) 
first order constant towards the “blood” compartment (hr-1) 
 
 
 
The “blood” compartment was assumed to communicate with the lung 
compartment and a “periphery” compartment with elimination of the drug due 
to hepatic and renal clearance mechanisms.  
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( ) P21B1210LLB CkCkkCkdt
dC
⋅+⋅+−⋅=  (6) 
 
P21B12
P CkCk
dt
dC
⋅−⋅=  
 
(7) 
CB 
VB 
Cp 
k12, k21 
k10 
Ciprofloxacin concentration in the “blood” compartment (µg/ml) 
blood volume (mL) 
Ciprofloxacin concentration in the “periphery” compartment (µg/ml) 
first order constant towards and from the “periphery” compartment (hr-1) 
first order constant for elimination of drug from blood compartment (hr-1) 
 
 
 
Colino et al. investigated the response of i.v. injection of Ciprofloxacin in 
rabbits [44]. The parameters that were estimated in the study were fixed in this 
work and are tabulated in table 1. The model given by equations (1)-(7) was 
fitted to the Ciprofloxacin levels in the blood of animals treated with the 
liposomes, and AVT. For the estimation of the PK parameters a non-linear 
extended least squares regression analysis, as implemented in the SAAM II 
software (University of Washington and SAAM institute, Seattle, WA) was used. 
 
Table 1. Pharmacokinetic parameters fixed from literature 
Parameter Value 
k12 3.06 (hr-1) 
k21 1.25 (hr-1) 
k10 1.7 (hr-1) 
 
The integrator was based on the Rosenbrock method and the optimizer 
was a modification of Gauss-Newton method [45-47]. The objective function that 
was minimized was the following extended least squares function: 
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M 
yi,j ti,j 
p 
s(p, ti,j) 
Vi,j 
vj 
 
the sum of all data points across all data sets 
the i-th data and time point in the j-th data set 
vector of the estimated parameters 
the model prediction at time i in the j-th data set 
the measurement error at time i in the j-th data set 
the posteriori variance factor of the j-th data set 
 
In our case the model was used to fit one set of experimental data. Since 
the data were expressed as mean value (±standard deviation), the model 
accounted for the error of the data. 
( ) ( ) nieptt iii ,...,1,,yy calobs =+=  (9) 
 
yobs 
ycalc 
p 
ej 
 
the random vector of measurements 
known function describing the kinetics 
the random vector for kinetic model parameters 
the measurement error random vector 
 
 
The objective function was optimized in order to minimize the difference 
between the experimental and the simulated data. Therefore, the objective 
function was weighted by the error variance and hence the parameter confidence 
limits would be a function of data reliability. 
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The minimum number of calculation intervals was set at 200 and the 
maximum number of fit iterations was set at 50 based on central difference 
derivative. The convergence criterion was set to 10-7. Convergence was achieved 
when one of the two criterions was satisfied:  
1. The difference between the value of the linear approximation of the 
objective function at the current parameter estimate and the minimum 
value of the linear approximation was less than ε, where ε equaled 10-7 
times the value of the linear approximation at the current parameter 
estimate. 
2. The solution to a linear approximation of the objective function was 
within δ for each parameter, where the default value of δ equaled 10-7 
times the difference between the upper and lower bounds for that 
parameter.  
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3.3. Experimental procedures of the 2nd generation of AVT (in 
vivo cleavable) 
In this section the in vitro and in vivo experiments that were undertaken 
to demonstrate modulation of release after cleavage with cysteine are described. 
The aliphatic disulfide cross-linker dithiobis[succinimidylpropionate] (DTSSP) 
was used in making the agglomerates.  
3.3.1. In vitro studies with blank liposomes 
3.3.1.1. Materials 
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA, 
USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).  
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc 
(Alabaster, AL, USA). The cross-linker DTSSP was purchased from Pierce 
(Rockford, IL, USA). All the rest of the reagents were purchased from Fisher 
Scientific. 
3.3.1.2. Fabrication and characterization of liposomes 
The liposomes were made by extruding a suspension of dissolved 
hydrated lipids through a single 400 nm Whatman Nuclepore polycarbonate 
trach-etch membrane in a Lipex Biomembranes extruder (Vancouver, British 
Columbia, Canada). A lipid composition of 57% DPPC, 40% Cholesterol, and 3% 
DSPE-PEG-NH2 conjugate was used. The lipids were dissolved in ethanol at 50-
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600 C and then hydrated with sodium citrate buffer (ethanol volume not 
exceeding more than 10% of the final volume), the lipid concentration in the final 
mixture being 100 mM. The suspension was then passed 7-10 times through the 
extruder at 50-540C and a pressure of approximately 100 psi. The liposomes were 
characterized by DLS. 
 
3.3.1.3. Agglomeration and characterization of blank agglomerates 
Liposomes (~50 mM lipid content) were agglomerated using DTSSP as the 
linker. The amount of DTSSP used was a 20 fold molar excess over the number of 
PEG-NH2 groups on the outer leaflet of the liposomes. The pH of the reaction 
mixture was maintained at ~ 7.4 (the optimal pH for DTSSP activity is in the 7-8.5 
range). The linker was added slowly over 10 minutes to the liposomes with 
constant stirring, with the agitation maintained for 1.5 hours. 
The agglomerates were split into batches and treated with different 
amounts of cysteine at 37 0C to induce cleavage of the disulfide linkage in the 
cross-linker. The sizes of the agglomerates before and after cleavage were 
measured Fraunhofer diffraction. 
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3.3.2. In vitro studies with carboxyfluorescein loaded liposomes 
3.3.2.1. Materials 
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA, 
USA). Cholesterol and 1,4-diazabicyclo[2.2.2]octane (Dabco) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  DSPE-PEG-NH2 conjugate was purchased 
from Avanti Polar Lipids Inc (Alabaster, AL, USA). The cross-linker DTSSP was 
purchased from Pierce (Rockford, IL, USA). 5-(and-6)-carboxyfluorescein was 
purchased from Invitrogen Corp. (Carlsbad, CA, USA). The other reagents were 
purchased from Fisher Scientific. 
 
3.3.2.2. Fabrication and characterization of liposomes 
A lipid composition of 57% DPPC, 40% Cholesterol, and 3% DSPE-PEG-
NH2 conjugate was used. The lipids were dissolved in ethanol at 550 C and then 
hydrated with a 5 mM carboxyfluorescein solution made in saline (150 mM 
NaCl) (ethanol volume not exceeding more than 10% of the final volume). The 
liposomes were made by extruding the suspension of the hydrated dissolved 
lipids through a single 400 nm Whatman Nuclepore polycarbonate trach-etch 
membrane in a Lipex Biomembranes extruder (Vancouver, British Columbia, 
Canada). The lipid concentration in the mixture was 100 mM. The suspension 
was then passed 7-10 times through the extruder at 50-54 0C and a pressure of 
approximately 100 psi. 
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The extruded liposomes were then diafiltered for over 3 hours using 50 
nm cutoff tubings with the external phase of the liposomes being replaced with 
saline (150 mM) at pH of ~7.2 in order to remove ethanol and unencapsulated 
carboxyfluorescein. The diafiltration was stopped when the external phase 
collected during the diafiltration was colorless. The liposomes were 
characterized for size by DLS. 
 
3.3.2.3. Agglomeration and characterization of carboxyfluorescein 
agglomerates 
Liposomes (~50 mM lipid content) were agglomerated using DTSSP as the 
linker. The amount of DTSSP used was a 20 fold molar excess over the number of 
PEG-NH2 groups on the outer leaflet of the liposomes. The pH of the reaction 
mixture was maintained at ~ 7.4 (the optimal pH for DTSSP activity is in the 7 - 
8.5 range). The linker was added slowly over 10 minutes to the liposomes with 
constant stirring, with the agitation maintained for 1.5 hours. 
The sizes of the agglomerates were characterized by Fraunhofer 
diffraction. 
 
3.3.2.4. Visual analysis of agglomerates by Confocal microscopy 
The agglomerates were diluted in saline containing 25 g/L of Dabco to 
inhibit the photobleaching of the fluorescent dye. A drop of the diluted 
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agglomerates was placed on a glass slide and a cover slip was placed over it. The 
agglomerates were observed under a Zeiss LSM 510 META confocal microscope 
using a ×63 immersion oil objective (Carl Zeiss, Germany) in the multi-track 
scanning mode with excitation wavelengths set at 488 nm (Argon laser); emission 
wavelengths were 505 to 530 nm for signal detection. Single optical slices were 
set to 0.8 µm and Z-stack slices to 0.5 µm.  
 
3.3.3. In vitro studies with Ciprofloxacin loaded liposomes 
3.3.3.1. Materials 
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA, 
USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).  
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc 
(Alabaster, AL, USA). The cross-linker DTSSP was purchased from Pierce 
(Rockford, IL, USA). Ciprofloxacin (Bayer Pharmaceutical Corp, West Haven, 
CT, USA) was purchased from a local pharmacy as Cipro-I.V. solution and 
purified as follows: The pH of Cipro-I.V. solution was raised from 2.1 to 7 with 
sodium hydroxide to precipitate the Ciprofloxacin. The suspension was then 
centrifuged at 1500 x g (4000 rpm) for 10 minutes, and the supernatant discarded. 
The powder was then washed with DI water and centrifuged 4 times to remove 
lactic acid (an inert excipient in the i.v. solution). A final wash and centrifugation 
with ethanol yielded a wet powder which was collected and dried in a vacuum 
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desiccator. Ciprofloxacin yield was 90%. Survanta® was purchased from Abbot 
Laboratories (Abbott Park, Illinois, USA). All the rest of the reagents were 
purchased from Fisher Scientific (Hampton, NH, USA). 
3.3.3.2. Fabrication and characterization of liposomes 
A lipid composition of 57% DPPC, 40% Cholesterol, and 3% DSPE-PEG-
NH2 conjugate was used. The lipids were dissolved in ethanol at 550 C and then 
hydrated with a 400 mM ammonium sulfate solution (ethanol volume not 
exceeding more than 10% of the final volume). The liposomes were made by 
extruding the suspension of the hydrated dissolved lipids through a single 400 
nm Whatman Nuclepore polycarbonate trach-etch membrane in a Lipex 
Biomembranes extruder (Vancouver, British Columbia, Canada). The suspension 
was then passed 7 times through the extruder at 50-54 0C and a pressure of 
approximately 100 psi. The liposomes were characterized by DLS. 
3.3.3.3. Loading of liposomes with Ciprofloxacin 
Ciprofloxacin was loaded into liposomes by the ammonium sulfate 
gradient method [36]. Liposomes were diafiltered for 1-2 hours using 50 nm 
cutoff tubings with the external phase of the liposomes being replaced with 
saline (150 mM) at pH of ~5.3 in order to remove ethanol and unencapsulated 
ammonium sulfate. For the remote loading procedure, Ciprofloxacin was 
dissolved in saline (60 mg/ml) at pH 4.2 and 60ºC, and was gradually added (0.5 
ml added every 3-5 minutes) to the liposomal suspension with the temperature 
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maintained at 60ºC. The loading was terminated after 1 hour by rapidly 
dropping the temperature using an ice bath. The drop in temperature reduces the 
permeability of the liposome bilayer thus preventing the transfer of species 
across the bilayer and entrapping the loaded drug. Finally, the suspension was 
separated from unencapsulated Ciprofloxacin by overnight dialysis against 
saline solution (100 times volume of liposomes) at pH 5.3. 
3.3.3.4. Agglomeration and characterization of Ciprofloxacin loaded 
liposomes 
Liposomes were agglomerated using DTSSP as the linker. The amount of 
DTSSP used was a 10 – 20 fold molar excess over the number of PEG-NH2 
groups on the outer leaflet of the liposomes. The pH of the reaction mixture was 
maintained at ~ 7.4 (the optimal pH for DTSSP activity is in the 7-8.5 range). The 
agglomerates were characterized for size by Fraunhofer diffraction. 
 
3.3.3.5. Visual analysis of agglomerates by negative stain electron 
microscopy 
The morphology of the agglomerates of DTSSP preparations was 
examined by negative staining electron microscopy (EM). Copper grids coated 
with colloid-ion-carbon and freshly glow discharged were used for sample 
adsorption.  Each grid was floated on a drop of sample for 5 min. Excess fluid 
was removed by blotting with a filter paper, and the grid was  washed for 2 
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seconds on a drop of water, floated on a drop of 1% uranyl acetate for 15 
seconds, and air dried for 2-5 minutes. All electron micrographs were taken with 
a JEOL JEM1230 electron microscope operating at 80 kV and 56 µA beam current. 
 
3.3.3.6. Release studies 
The release of Ciprofloxacin from agglomerates before and after cleavage 
with cysteine was evaluated in vitro. 1 ml of Ciprofloxacin loaded agglomerates 
(14 mM lipid) and 400 µl Survanta® was incubated at 37 °C in a dialysis bag 
(100,000 MWCO) immersed in PBS at a pH of 7.4. The volume of the external 
phase was 20 times that of the internal phase. Samples from the external phase 
were taken and were assayed for Ciprofloxacin in the HPLC.  
At different time points cysteine (8.7 mg/ml in total volume of dialysis 
bag equivalent to 70 mM) was spiked into the dialysis bag, in an attempt to 
trigger the release. To show that the modified release from the agglomerates was 
due to cysteine and not due to any other factors, a separate study was done were 
a volume of plain buffer equivalent to that of cysteine (50 µl) was introduced at 
similar time points. At the end of the experiment the contents of the dialysis bag 
were also assayed for Ciprofloxacin content. 
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3.3.4. In vivo cysteine triggered release studies 
3.3.4.1. Materials 
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA, 
USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).  
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc 
(Alabaster, AL, USA). The cross-linker DTSSP was purchased from Pierce 
(Rockford, IL, USA). Fluorescently tagged lipid, N- (7-nitrobenz-2-oxa-1, 3-
diazol-4-yl)-1, 2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE) 
was purchased from Invitrogen Corp. (Carlsbad, CA, USA). Ciprofloxacin (Bayer 
Pharmaceutical Corp, West Haven, CT, USA) was purchased from a local 
pharmacy as Cipro-I.V. solution and was purified as described in section 3.3.3.1. 
 
3.3.4.2. Animals 
New Zealand White male rabbits (2.9 ± 0.5 kg) were purchased from 
Myrtle Rabbitry (Thompson Station, TN, USA). Male Sprague Dawley rats (330 – 
350 gm) were purchased from Harlan (Indianapolis, IN, USA). The use of 
animals for this study was approved by the Center for Laboratory Animal 
Medicine and Care (CLAMC) of UTHSC-Houston. Care and handling of the 
animals was in accordance with all policies of the United States Department of 
Agriculture (USDA) and U.S. Public Health Service (PHS). 
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3.3.4.3. Fabrication and characterization of liposomes 
3.3.4.3.1. Ciprofloxacin loaded liposomes 
A lipid composition of 57% DPPC, 40% Cholesterol, and 3% DSPE-PEG-
NH2 conjugate was used. The liposomes were made by following the procedure 
described in section 3.3.3.2. The liposomes were remotely loaded with 
Ciprofloxacin following the same steps as in section 3.3.3.3.    
3.3.4.3.2. Liposomes with fluorescent labeled lipid 
A lipid composition of DPPC:CHOL:DSPE-PEG-NH2:NBD-PE (56:40:3:1, 
mol%) was used. After ethanol dissolution the lipids were hydrated with 150 
mM NaCl solution (ethanol volume not exceeding more than 10% of the final 
volume). The liposomes were made by extruding the suspension of the hydrated 
lipids 7 times through a single 400 nm Whatman Nuclepore polycarbonate trach-
etch membrane in a Lipex Biomembranes extruder at 50-54 0C and a pressure of 
approximately 100 psi. The liposomes were size characterized by DLS. 
 
3.3.4.4. Preparation and characterization of agglomerated liposomes 
Liposomes with a lipid content of 50 mM were agglomerated using DTSSP 
as the linker. The amount of DTSSP used for the agglomeration was a 10 - 20 fold 
molar excess over the PEG-NH2 groups on the outer leaflet of the liposomes. The 
cross-linking reaction was carried out at a pH of 7.4 (optimal for cross-linking 
 72 
activity of DTSSP) with constant stirring for 1.5 hours. The size distribution of 
the agglomerates was determined using the Fraunhofer diffraction technique. 
 
3.3.4.5. Pharmacokinetic study in rabbits 
Rabbits were anesthetized by a subcutaneous injection of 
ketamine/xylazine (40-50/5-10 mg/kg). The rabbits were maintained on 2% 
isoflurane and O2 (1 lit/minute). The heart rate, temperature and O2 were 
monitored periodically, and remained stable throughout the course of the 
experiment. 
The marginal ear vein was accessed via an i.v. catheter (24 G). The catheter 
was taped to the ear. Using a laryngoscope, an endotracheal tube (size 3) was 
inserted into the trachea, with a urinary catheter acting as a guide. Insertion into 
trachea was confirmed with a stethoscope, by pumping air into the lungs. The 
cuff of the endotracheal tube was filled with air to maintain the tube in the 
trachea. Additionally, the tube was tied to the mouth to retain it in place. 
The rabbit’s head was maintained in an upright position and drug 
formulation was instilled into the lungs with a syringe. The formulation was 
pushed down by forcing air into the lungs with the syringe several times. 2.2 to 
2.8 ml of formulation (corresponding to Ciprofloxacin doses of 17 ± 1.6 mg/kg) 
was instilled. 
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Blood was drawn from the ear vein before (time 0) and after instillation of 
drug formulation. Blood samples were centrifuged at 13,400 rpm for 15 minutes 
to separate the plasma from cell components. The plasma was then diluted 1:4 
times with methanol: phosphate buffer (9:1 v/v) to precipitate the proteins 
present in the sample. The resulting suspension was then centrifuged at 13,400 
rpm in a microcentrifuge for 15 minutes and the supernatant was assayed for 
Ciprofloxacin content by HPLC. Standard curve for Ciprofloxacin was 
determined by spiking known amounts of Ciprofloxacin in rabbit plasma. The 
lowest detection limit by HPLC was 0.05 µg/ml. 
The agglomerates made with the cross-linker DTSSP that were used in the 
in vivo pharmacokinetic studies are termed as AVT2. Two sets of studies were 
done with these agglomerates. In the first study the agglomerates were instilled 
as described above, and their drug release was monitored.  
In the second study, 1 ml cysteine (60 mg/ml) was introduced in to the 
lungs 90 minutes after instillation of AVT2, to cleave the agglomerates and alter 
the release of Ciprofloxacin into the blood. The rabbits recovered from anesthesia 
and were returned to their cages after 6 hours. After 24 hours, the rabbits were 
anesthetized and intubated again and cysteine solution was instilled again. Blood 
was drawn at all the time points as described earlier. 
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3.3.4.6. Lipid assay of instilled formulations in rat lungs 
To measure lipid elimination as a function of particle size and correlate it 
to drug release, fluorescently tagged liposomes and agglomerates were instilled 
in the lungs of rats and the residual fluorescence in lung tissue assayed over a 48 
hour period. 
Male Sprague Dawley rats were anesthetized with an intraperitoneal (i.p.) 
injection of ketamine (80 mg/kg body wt.) and xylazine (10 mg/kg body wt.). 
The rats were endotracheally intubated with a 16 G catheter. The endotracheal 
tube was then connected to a ventilator and under forced ventilation; successful 
intubation was confirmed if the chest of the rat expanded with the same 
frequency as the ventilator.  200 µL of the liposomal and agglomerate 
formulation (50 mM lipid content) with the fluorescent tagged lipids were 
instilled into the lungs of the rats. The total lipid dosed was 4078.78 ± 506.07 
µg/gm of lung wt. In a separate study 100 µL of cysteine (60mg/ml) was instilled 
after 4 minutes from the instillation of the cleavable agglomerates (made with 
DTSSP). At 2, 24, and 48 hours post-instillation of the liposomes and 
agglomerates, the rats were euthanized with an overdose of pentobarbital (200 
mg/kg) administered i.p. and the lungs were collected for the lipid assay. 
The collected lungs were refrigerated and were processed within a few 
hours of extraction. For the lipid extraction a modification of the method of 
Matot et al. [48] was used. Briefly, the lungs were weighed, chopped and then 
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homogenized in cold chloroform/methanol (2:1 vol.) mixture. The homogenized 
tissue was filtered through Whatman filter paper no. 1. The collected filtrate was 
then assayed for fluorescence in a SpectraMax GeminiXS spectrofluorometer 
(Molecular Devices Corp, Sunnyvale, CA, USA) with filter settings of 463 nm 
excitation and 530 nm emission wavelengths. (Calibration standards were made 
by spiking known amounts of the tagged liposomes into the filtrate collected 
from the lungs of untreated rats.) The fluorescence intensity associated with the 
known lipid from the liposomes was used to determine the amount of lipid that 
remained in the lungs after instillation of the liposomes and the agglomerates. 
 
3.3.4.7. Histology of rat lungs to assess inflammation 
Male Sprague Dawley rats were anesthetized with an i.p. injection of 
ketamine (80 mg/kg body wt.) and xylazine (10 mg/kg body wt.). The rats were 
endotracheally intubated with a 16 G catheter following the same procedure as 
described in section 3.3.4.6. In separate studies, formulations of (1) 20 µL of saline 
(-ve control), (2) 40 µL of ConA solution (+ve control) containing 2.4 mg 
ConA/kg body weight, (3) 20 µL of liposomes containing 0.41 mg of lipids/kg 
body weight, and (4) 30 µL of AVT particles containing 1.74 mg of lipids/kg 
body weight were instilled in the lungs of the rats. The rats were recovered from 
anesthesia and returned to their cages. 
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 After 24 hours post-instillation the rats were euthanized with an overdose 
of pentobarbital (200 mg/kg) administered via an i.p. injection and the lungs 
were collected. The lungs were gently inflated with 10% neutral buffered 
formalin until resistance was appreciated, and then immersed in formalin 
overnight. The next day, the lungs were serially sectioned and submitted for 
routine histological processing and paraffin embedding. Five micron-thick 
sections were cut from each paraffin block and placed on glass slides, which 
were stained with a standard hematoxylin-eosin (HE) stain. These slides were 
reviewed by a practicing pathologist and evaluated semi-quantitatively for 
changes of edema, inflammation and other histological abnormalities. The 
inflammation triggered by the preparations was rank-ordered by the pathologist. 
  
3.3.4.8. Cytokine assay from rat lungs as a measure of inflammation 
Male Sprague Dawley rats were anesthetized with an i.p. injection of 
ketamine (80 mg/kg body wt.) and xylazine (10 mg/kg body wt.). The rats were 
endotracheally intubated with a 16 G catheter following the same procedure as 
described in section 3.3.4.6. In separate studies, formulations of (1) 250 µL of 
liposomes (50 mM lipids; 34.7 mg lipid/ kg body wt.), (2) 250 µL AVT (50 mM 
lipids; 34.7 mg lipid/ kg body wt.), (3) 250 µL of saline (-ve control), and (4) 50 µL 
of ConA solution (+ve control) containing 4.1 mg ConA/kg body wt. were 
instilled in the lungs of the rats. The Ciprofloxacin content of the liposomes and 
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AVT was 18 mg/ml. The rats were recovered from anesthesia and returned to 
their cages. 
After 48 hours post-instillation the rats were euthanized with an overdose 
of pentobarbital (200 mg/kg) administered via an i.p. injection. The trachea was 
exposed and a Teflon tubing with ~1.2 mm i.d. was inserted into the trachea and 
held in place with a suture. An 18G needle adapter with a syringe was attached 
to the tubing. The lungs were lavaged twice with 4 ml of sterile filtered (0.22 
micron) PBS (10 mM phosphate, 150 mM NaCl). After instilling the lavage, the 
chest and the abdomen of the rats were massaged for 30 seconds and then the 
instilled fluid was aspirated. Total volume of the bronchoalveolar lavage (BAL) 
collected was between 5-6 mls. The collected BAL was stored on ice till the 
centrifugation step for ~ 3hrs. The BAL was centrifuged for 5 mins at 1000 g’s at 
4 0C. The supernatant was collected and stored at -20 0C till the assay for 
cytokines. 
Four cytokines, viz. IL-2, IL-6, TNF-α, and IFN-γ were assayed 
simultaneously in a multiplex panel using a Bio-Rad Bio-Plex cytokine assay kit 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). The collected samples were 
thawed prior to assay. The instructions provided in the manual of the kit were 
followed to prepare the standards and samples in the suspension plate. The plate 
contents were read in a Bio-Rad Bio-Plex system powered by Luminex Xmap 
technology.  
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3.3.5. In silico study of Ciprofloxacin pharmacokinetics of the 2nd 
generation AVT 
A mechanistic/deterministic compartmental model was employed as 
already described in section 3.2.4 to analyze the Ciprofloxacin profiles obtained 
from the pharmacokinetic studies.  
In aaddition to the parameters already incorporated in the model, an 
additional term (α’’) was introduced in the input bolus term of the AVT and the 
lungs. This term takes into account the burst in release of drug from the AVT 
particle at the time point when exogenous cysteine is introduced into the lungs. 
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Chapter 4 
Results and Discussions 
4.1. The 1st Generation of AVT (in vivo non-cleavable)  
In this section the results of the efforts undertaken to fabricate the first 
generation of agglomerated liposomes and test them in vitro and in vivo are 
presented. The linker (DTBP) that was used to make the agglomerates is not 
cleavable in vivo.  
4.1.1. In vitro experiments with blank liposomes 
4.1.1.1. Characterization of liposomes 
Two sets of blank liposomes of 100 mM lipid content with 2% and 3% 
PEG-NH2 conjugate in the bilayer were made. These were utilized to make 
agglomerates under different conditions. The DLS results of the liposomes 
extruded through the 400 nm polycarbonate membrane are shown in figure 14.  
The DLS analysis suggested that the liposomes with 2% PEG-NH2 had a 
size distribution between 180 – 440 nm with a mean diameter of 275.5 nm. The 
liposomes with 3% PEG-NH2 showed a broader distribution between 165 – 765 
nm with a mean diameter of 264.4 nm. These results are consistent with the 
extrusion process of liposomes as reported by Sood [49]. The size of the 
liposomes depends on a number of factors including lipid content, temperature, 
pressure, buffer, pore size of the membrane, and number of passes.  
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Figure 14. DLS results of blank liposomes with 2% PEG-NH2 and 3% PEG-NH2 used 
for making agglomerates of DTBP. 
 
Particles in the 1-5 nm range were also detected in DLS. These are most 
likely to be micelles of the DSPE-PEG-NH2 conjugate that are formed during the 
hydration process and are not incorporated in the lipid bilayer of the liposomes – 
a normal occurrence observed with liposomes made with the PEG moiety 
anchored to a lipid.  
 
4.1.1.2. Agglomeration of liposomes with DTBP 
This preliminary study was undertaken to see how the amount of 
reactants would affect the sizes of the agglomerates formed. In addition to this 
the time-progression of the agglomeration process was also studied. Table 2 lists 
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reaction conditions that were utilized for this study. The amount of the cross-
linker DTBP used was in excess (molar basis) of the number of reacting groups 
on the PEG conjugate present on the external surface of the liposomes. 
 
Table 2. Reaction conditions that were used for making the agglomerates of blank 
liposomes with DTBP cross-linker. 
Mol% PEG-NH2 
 
Lipid molarity of 
liposomes (mM) 
Molar excess of DTBP used over PEG-
NH2 present in the external bilayer of 
the liposomes 
10 25, 50, and 100 times 
20 25, 50, and 100 times 
2 
 
50 25, 50, and 100 times 
10 25, 50, and 100 times 
20 25, 50, and 100 times 
3 
 
50 25, 50, and 100 times 
 
As an example of the time progression of the agglomeration reaction, 
figure 15 shows the Fraunhofer diffraction results of liposomes (2% PEG-NH2) 
agglomerated with 50 times molar excess of DTBP (figure 15 a), and liposomes 
(3% PEG-NH2) agglomerated with a 25 times molar excess of DTBP (figure 15 b). 
The reactions were stopped by taking aliquots of the reaction mixture and 
quenching them in a reservoir of Tris buffer (300 mM). During the initial time 
points (5 mins and 25 mins) the sizes are broadly distributed from the sub-
micron range (< 1 µm) to 100 µm. As the time of the reaction progressed the 
particles in the sub-micron range were consumed resulting in bigger sizes as 
observed by the disappearance of sub-micron sized liposomes. After 2 hours a 
unimodal distribution was observed with a mode at 6.4 µm (figure 15a) and 11.1 
µm (figure 15b). Particles bigger than 40 µm that are observed at 5 and 25 
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minutes are no longer seen after 1 hour. The reason for this could be the 
fragmentation of these bigger particles into the smaller size range possibly due to 
the effects of stirring.  
 
Figure 15. Time progression of agglomeration reaction of liposomes (50 mM lipid) 
carrying (a) 2% PEG-NH2 with 50 times DTBP, and (b) 3% PEG-NH2 with 25 times 
DTBP. The reactions were stopped with Tris and evaluated by Fraunhofer diffraction. 
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Figure 16. Size distributions of agglomerates obtained by Fraunhofer diffraction after 
using different molar excess of DTBP linker over 3% PEG-NH2. Liposomes used were (a) 
20 mM lipid, and (b) 50 mM lipid. The agglomerates were measured after 3 days from 
the start of the reaction.  
 
The agglomerates were analyzed after 3 days from the start of the 
reaction. The reaction was not quenched with Tris after 2 hours, since the cross-
linker loses its activity within a few hours. The sizes of the agglomerates 
Agglomerates (50 mM lipid), 3% PEG-NH2, after 3 days
0
1
2
3
4
5
6
7
8
0.1 1 10 100 1000
Size(µm)
%
F
re
q
u
en
cy
25 times DTBP
50 times DTBP
100 times DTBP
b
Agglomerates (20 mM lipid), 3% PEG-NH2, after 3 days
0
1
2
3
4
5
6
7
8
9
0.1 1 10 100 1000
Size(µm)
%
F
re
q
u
en
cy
25 times DTBP
50 times DTBP
100 times DTBP
a 
 84 
achieved with different amounts of linker for the same lipid molarity of the 
liposomes were compared. As an example, figure 16 shows the size distribution 
of the agglomerates of liposomes (3% PEG-NH2) having a lipid molarity of 20 
mM (figure 16a) and 50 mM (figure 16b) achieved with the different amounts of 
DTBP. The size distributions were unimodal with the sizes ranging from 3 – 40 
µm. In case of the 20 mM lipids (figure 16a), the agglomerates had modes at 13.3, 
11.1, and 8.4 µm made with 25, 50, and 100 times DTBP respectively. For the 50 
mM lipids (figure 16b), the agglomerates had modes at 12, 9.2, and 7 µm made 
with 25, 50, and 100 times DTBP respectively.  
A common trend was observed wherein; the agglomerates formed with 
less amount of linker were bigger than the agglomerates formed with higher 
amounts. A possible explanation to this could be that the higher amount of linker 
used reacts at a faster rate with the NH2 groups present on the liposomal surface. 
Due to the higher bulk concentration of the reactants present at the start, the 
initial collisions result in the formation of the agglomerates quickly. But as the 
reaction sites on the liposomal surface start getting consumed by the smaller and 
faster diffusing cross-linker molecules, no more sites are available for linking the 
agglomerates formed that have a lower diffusion rate owing to their larger sizes. 
In the case of the lower amounts of the linker used, the time for this saturation is 
possibly slower resulting in more interaction between the activated and 
inactivated sites that results in the formation of slightly bigger agglomerates. 
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A similar trend was seen when liposomes with different molarities (the 
lipid molarity is proportional to the number of liposomes of the same size) were 
reacted with the same molar excess of DTBP.  Figure 17 shows an example of the 
same. 
  
Figure 17. Size distributions of agglomerates obtained by Fraunhofer diffraction after 
using liposomes with different lipid molarities with 100 molar excess of DTBP over (a) 
2% PEG-NH2, and (b) 3% PEG-NH2 on liposomes. The agglomerates were measured 
after 3 days from the start of the reaction. 
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A lower lipid molarity of the liposomes resulted in larger agglomerates in 
comparison to a higher lipid molarity. The agglomerates of liposomes with 2% 
PEG-NH2 (figure 17a) had a unimodal distribution with modes at 3.35, 8.4, and 
13.3 µm for 50, 20, and 10 mM of lipid. The agglomerates of liposomes with 3% 
PEG-NH2 (figure 17b) also had a unimodal distribution with modes at 7, 10, and 
16 µm for 50, 20, and 10 mM of lipid. 
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Figure 18. Fraunhofer diffraction results showing the effect of pH on the 
agglomeration of the liposomes. 
 
During the agglomeration reaction it was observed, that the pH of the 
mixture drifted from 8.15 to a lower pH of ~5.6 after addition of the linker. In the 
previous results reported the pH was adjusted to 8.15 immediately after the 
addition of the linker since the cross-linker is active at this point. To test if the 
drift in pH affects the agglomeration reaction (ultimately affecting the size), 
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liposomes (50 mM lipid) were reacted with DTBP (100 molar excess). The 
Fraunhofer diffraction results shown in figure 18 clearly suggest that the pH 
affects the extent of agglomeration. It was observed that the agglomeration was 
incomplete when the pH was not adjusted as evidenced by the presence of sub-
micron sized liposomes. This suggested that the activity of the cross-linker is lost 
when the reaction is not carried in the optimal pH range. 
 
4.1.2. In vitro studies with Ciprofloxacin loaded liposomes 
4.1.2.1. Characterization of Ciprofloxacin loaded liposomes 
The size distribution of Ciprofloxacin loaded liposomes is shown in figure 
19. The liposomes, extruded through the 400 nm polycarbonate membrane, were 
in the range of 180-195 nm.  
After removal of the unencapsulated Ciprofloxacin, the concentration of 
the encapsulated drug, determined by HPLC analysis, was 10.5 mg/mL, 
representing 90% of the initial amount added during the loading procedure.  
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Figure 19. Size distribution of Ciprofloxacin loaded liposomes. 
 
4.1.2.2. Agglomeration of Ciprofloxacin loaded liposomes with DTBP 
Figure 20 shows a comparison of the size distribution (measured by 
Fraunhofer diffraction) Ciprofloxacin loaded liposomes agglomerated with 
DTBP at pH 5.2 (Prep I) and 8.5 (Prep II). In the case of Prep I, large agglomerates 
exhibiting sizes between 4 – 60 µm and a mode at 21 µm were seen.  A mode at < 
1µm persists, suggesting that the parent liposomes have not been fully 
agglomerated. In the case of Prep II, it was observed that the agglomerates 
exhibited a very broad size distribution. These large agglomerates had sizes 
between 1-160 µm and a mode at 34 µm.  It was observed that the mode for 
unagglomerated liposomes does not appear, implying that the majority of the 
 89 
parent liposomes have been agglomerated. These results of pH effects on 
agglomeration are consistent with the studies done with blank liposomes.  
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Figure 20. Fraunhofer diffraction results of agglomerates of Ciprofloxacin loaded 
liposomes made at pH 5.2 and 8.5. 
 
However, the agglomerates of Prep II showed a 70% leakage of the 
encapsulated Ciprofloxacin even though the pH was brought back to 5.2 after the 
end of the agglomeration reaction (3 hours). On the other hand, only 10% of the 
encapsulated ciprofloxacin leaked out from the agglomerates of Prep I, since the 
pH was maintained at 5.2, which was the pH throughout the remote loading 
procedure. The leakage was tested by performing a dialysis experiment on the 
agglomerates preparations and assaying the external phase of the dialysis bag for 
Ciprofloxacin by HPLC. 
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DTBP is cleavable by aggressive thiols like DTT (which is not suitable for 
in vivo use). The Prep II agglomerates were cleaved with different amounts of 
DTT at 37 0C. The results in figure 21 show that the extent of cleavage was more 
when more DTT was used. This is evident by the increase in the fraction of 
particles in the 1-20 µm, and fall in the fraction of agglomerates larger than 40 
µm. However, the cleavage was not extensive, i.e. it did not result in the 
formation of parent liposomes. It was anticipated that this cleavage of the 
agglomerates would result in accelerated release of the drug. 
0
1
2
3
4
5
6
7
0.1 1 10 100 1000
Size (µm)
%
 F
re
q
u
en
cy
Agglomerated Liposomes (Prep II)
Agglomerated Liposomes (Prep II) cleaved with 30 mg/mL
DTT
Agglomerated Liposomes (Prep II) cleaved with 60 mg/mL
DTT
 
Figure 21. Size analysis of agglomerates of Ciprofloxacin loaded liposomes before and 
after cleavage with 30 and 60 mg/ml of DTT at 37 0C. 
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4.1.2.3. Aerodynamic characterization of agglomerates 
Figure 22 shows the results of the cascade impactor studies done with 
liposomes agglomerated with DTBP, containing Ciprofloxacin to evaluate the 
aerodynamic properties of the agglomerates. The results suggest that the 
aerodynamic diameter of the agglomerates makes them highly respirable. 
Approximately 60% of the agglomerates had aerodynamic diameters in the 
respiratory range (between 1-5 µm). These diameters are clearly much lower than 
the geometrical sizes of these agglomerates (Prep I) measured by Fraunhofer 
diffraction (4-60 µm geometrical diameters). This data would be consistent with 
either fragmentation of the agglomerates in the nebulizer or low density of the 
porous agglomerates resulting in lowered aerodynamic diameters. 
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Figure 22. Aerodynamic diameters of DTBP agglomerates (Prep I) determined by 
cascade impaction. 
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Approximately 25% of the nebulized Ciprofloxacin (encapsulated within 
agglomerates) was collected and assayed in the impactor. The collection 
efficiency was low possibly due to wall losses in the impactor and possible losses 
while re-dissolving the material deposited on the plates, the elbow piece and the 
after-filter of the impactor prior to the assay. It is also suspected that the low 
efficiency may be contributed by the nebulizer, but could be improved in the 
future by optimizing the choice of the nebulizer. 
4.1.2.4. Stability upon nebulization studies 
The collection of the nebulisate was not very efficient. Only about 15% of 
the nebulized Ciprofloxacin (in both the cases of liposomes as well as 
agglomerates) was trapped in the saline. The remaining Ciprofloxacin was lost to 
the walls of the collection flask and some to the atmosphere, carried by the air 
stream exiting the flask. The material deposited on the walls was not included in 
the analysis since it might have dried and hence disrupted the bilayer of the 
liposomes, resulting in leakage. Leakage measured was only for the 15% of the 
material that was collected in the collection medium. While it is possible that 
some selection of the larger sizes did occur in the process, we tend to discount 
this since the air velocities in the flask are very low and impaction distances to 
both the liquid surface and the walls are about the same. It is therefore believed 
that the 15% collection is representative of the overall nebulized material. 
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It was expected that nebulization would cause a partial disruption of the 
particles. This was reflected by an increase in size of the liposomes upon 
nebulization as shown by the DLS result in figure 23. 
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Figure 23. Effect of nebulization on the size of liposomes 
 
One would expect similar disruption of the agglomerated particles. The 
size distribution of agglomerates (Prep I) collected in saline upon nebulization as 
analyzed by the Fraunhofer method, is shown in figure 24. It was observed that 
the nebulization caused very little disruption of the agglomerates. The size 
distribution of the nebulisate had a mode at 12.1 µm, whereas the agglomerates 
exhibited a mode at 21 µm before nebulization. This disruption is suggested not 
only by the shift of the peak of the agglomerates but also by the appearance of 
more parent liposomes in the collected samples of nebulisate. 
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Figure 24. Effect of nebulization on the size of agglomerated liposomes. 
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Figure 25. Loss of encapsulated Ciprofloxacin from liposomes and agglomerates after 
nebulization. 
 
The nebulisate was assayed in order to measure the fraction of 
Ciprofloxacin remaining encapsulated after nebulization for both parent 
liposomes and the agglomerates. The results shown in figure 25 compare the loss 
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of the encapsulated Ciprofloxacin from the liposomes and the agglomerates. The 
results show a 41.74% loss of encapsulated Ciprofloxacin in the case of the 
liposomes, but on the other hand the agglomerated formulation showed a 
slightly lower loss of encapsulated drug. 36.71% of the encapsulated 
Ciprofloxacin was lost from the agglomerates.  
The size distribution and loss of drug results suggest that the 
agglomerates were largely intact upon nebulization. It is possible that the 
nebulization breaks the agglomerate bonds but not the liposomes themselves. 
However, Wong et al [50] have shown that the force required to pull out a biotin-
PEG-lipid (similar to NH2-PEG-DSPE in this study) from a liposome is lower 
than the force needed to break a streptavidin-biotin bond (analogous to the cross-
links in the study). Such pullout could result in leakage from the liposomes, such 
as observed in this study. The nebulisate contained more liposomes and smaller 
agglomerates than the pre-nebulized agglomerates supporting the fact that a 
pullout of a small number of liposomes from the agglomerates took place. It is 
therefore believed that the agglomerates remain largely intact during the 
nebulization process. 
 
4.1.2.5. Release studies 
Since each of the drug release experiments lasted for one or more days at 
37 0C, a loss in the surfactant’s activity was expected [51]. A possible degradation 
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of Ciprofloxacin was also expected due to the presence of proteolytic enzymes in 
the surfactant.  
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Figure 26. In vitro release of Ciprofloxacin from liposomes, and agglomerates (Prep I) 
with and without cleavage with DTT. Arrows indicate time points at which agglomerates 
were cleaved with DTT. 
 
Figure 26 provides a comparison between the release profiles of 
Ciprofloxacin from parent liposomes, agglomerates (Prep I), and agglomerates 
cleaved with DTT. The agglomerates exhibited a similar initial burst as that of 
the parent liposomes, however, the release reached a lower plateau much earlier 
(~ 2 hours) as compared to almost 5 hours in the case of the liposomes. This 
indicates that the structure of the agglomerates possibly plays a role in protecting 
the liposomes in the inner core of the agglomerate from being exposed 
immediately to the surfactant. The arrows indicate the time points when the DTT 
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was added to the agglomerate and surfactant mixture. The introduction of the 
cleaving agent resulted in more release of Ciprofloxacin from the agglomerates, 
which reaches a higher plateau after sometime following the addition of DTT. 
The addition of higher amounts of the DTT resulted in a relatively higher release 
of Ciprofloxacin. This result suggests that the cross-links in the agglomerates are 
cleaved by DTT, thus exposing the interior of the agglomerate structure to the 
surfactant that consequently results in more release.  This would be analogous to 
the reduction in size observed by Fraunhofer analysis (figure 21) upon cleavage. 
It was observed that after the last cleavage, the agglomerates released more drug 
than the parent liposomes. A possible explanation to this could be that the 
liposomes rearrange to form multi-lamellar vesicles (MLVs) in the presence of 
lung surfactant. Such a rearrangement would be hindered in the case of the 
agglomerated liposomes due to the cross-linkages. 
 
4.1.3. In vivo studies with Ciprofloxacin loaded liposomes 
4.1.3.1. Characterization of Ciprofloxacin loaded liposomes 
The size of the liposomes, that were not agglomerated, was in the range of 
160 to 400 nm with a mean of 330 nm. The size of liposomes that were 
agglomerated later with DTBP to form AVT1, was in the range of 150 – 300 nm 
with a mean of 260 nm. 
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In the case of the liposomes that were not agglomerated, the concentration 
of the encapsulated Ciprofloxacin was measured to be 26.4 mg/ml. This value 
corresponds to 64% of the initial amount of Ciprofloxacin used during loading. 
The concentration of encapsulated Ciprofloxacin of the liposomes used for 
making the AVT1 particles was measured to be 26.6 mg/ml, corresponding to 
80% encapsulation of the total amount of Ciprofloxacin used in the loading 
procedure. 
 
4.1.3.2. Agglomeration of liposomes with DTBP 
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Figure 27. Size distribution of agglomerates (AVT1) used in animal studies. 
 
Figure 27 shows the geometric size distribution of the agglomerates AVT1 
by Fraunhofer diffraction analysis. Less than 10% of the particles were in the 
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submicron size range. The agglomerate population was broadly distributed from 
1–140 µm with a mode at 31 µm. Upon performing a leakage study (by dialysis) 
after the agglomeration, the amount of Ciprofloxacin that leaked from the 
agglomerates was found to be less than 2%. The final encapsulated Ciprofloxacin 
concentration of AVT1 was 17.8 mg/ml. 
4.1.3.3. Pharmacokinetic studies in rabbits 
Figure 28 shows the blood levels of Ciprofloxacin after intratracheal 
instillation of the free Ciprofloxacin, liposome-encapsulated Ciprofloxacin, and 
AVT1 treatment. Each data point represents the mean and standard deviation of 
the group (3 rabbits per group). The difference of the means between groups was 
verified to be significant by variance analysis (Student’s t-test). A p-value less 
than 0.05 was used to confirm significant differences at the 95% confidence level. 
Table 3. Formulation of Ciprofloxacin instilled in the lungs of rabbits. 
Formulation 
Ciprofloxacin 
Dose (mg/kg) 
Molarity of lipids 
(mM) 
Drug:Lipid 
(molar) 
Liposome 21.07 ± 1.64 ~120 0.66 
AVT1 17.05 ± 0.44 ~50 1.07 
Free Ciprofloxacin 15.4 NA NA 
 
The doses of the drug formulations instilled in the rabbits are tabulated in 
table 3. It should be noted that Ciprofloxacin has a very low solubility at neutral 
pH. Ciprofloxacin at a concentration of 21.9 mg/ml was instilled in the lungs in 
this study to compare with the concentrations used in experiments involving 
liposomes and the AVT particles. To keep Ciprofloxacin in solution at this 
concentration, the pH of the formulation was maintained at ~3.1. The rabbit 
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treated with the free Ciprofloxacin formulation showed signs of distress (heavy 
panting) after instillation. When the lungs were observed post mortem, there 
were signs of extensive injury highlighted by the darkening of the lung tissue. 
Hence, no more rabbits were used to evaluate free ciprofloxacin. The lung injury 
may be attributed to the high concentration of Ciprofloxacin that is in immediate 
contact with the tissue and the low pH of the formulation. To the best of our 
knowledge there are no studies reporting inflammation of the lungs or toxicity 
effects due to administration of Ciprofloxacin to the lungs. No such signs of 
damage were observed in the lungs of the rabbits that were used to evaluate the 
liposomes and AVT particles. 
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Figure 28. Pharmacokinetic data for the different formulation tested in rabbits. (n=1 for 
the free Ciprofloxacin study, and n=3 for the other studies. Study with liposomes and free 
Ciprofloxacin was done over 2 days. The AVT studies were done over 1 day). 
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A burst in release was observed in the case of the free Ciprofloxacin 
during the 1st hour, which then rapidly dropped to low values and eventually 
went to zero at the end of 48 hours. Cmax in blood was measured to be 3.38 
µg/ml. This rapid release can be attributed to the fact that Ciprofloxacin is in 
direct contact with the tissue and is able to quickly diffuse out in the blood. An 
assay of the lungs of the rabbit at the end of 48 hours indicated no Ciprofloxacin 
remained in the lungs. 
In the case of liposomes, and AVT1, though an initial burst in release of 
drug was observed, it was much lower than that for free Ciprofloxacin. 
However, the AVT1 particles and liposomes show that they are capable of 
extended drug release in the blood. Cmax for the liposomal formulation was 0.34 
± 0.06 µg/ml and this level of drug in the blood was maintained through the 48 
hour period.  Cmax for AVT1 was observed to be 1.53 ± 0.04 µg/ml with the level 
gradually falling to 0.63 ± 0.08 µg/ml over 24 hours. Thus the entire curve for 
AVT1 was higher than that for liposomes, indicating a much higher systemic 
bioavailability. The lower initial release-burst for the liposomes and AVT1 
particles is consistent with the fact that the Ciprofloxacin is encapsulated within 
the particles and is not in direct contact with the lung environment. As the drug 
leaks out of the particles, it is transported rapidly to the bloodstream, but at no 
point is the free drug concentration in the lung high enough to cause a large 
spike in the blood levels as observed in the free Ciprofloxacin case.  
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Table 4. AUC0 – 24 for pharmacokinetic data of figure 28. 
Formulation Dose (mg/kg) AUC0 - 24 (µg/ml.hr) 
Liposome-encapsulated 
Ciprofloxacin 
21.07 ± 1.64 8.02 ± 2.3 
AVT1 17.05 ± 0.44 19.8 ± 0.12 
 
The areas under the concentration-time curves (AUC0 – 24) for AVT 1, and 
liposomes for 24 hours were computed and are listed in table 4. The AUC’s 
increase with the size of the particles, suggesting that the larger particles have an 
improved systemic bioavailability in comparison to the smaller particles. 
4.1.4. In silico study of pharmacokinetics of 1st generation AVT  
The input dose (known parameter) for the liposomes and AVT1 particles 
are tabulated in table 5. The internal volume of the liposomes (VLips), and AVT1 
(VAVT) that were instilled, were fixed at 2 ml. The surfactant volume of the 
rabbits was assumed to be 1.8 ml. This volume of the pulmonary fluid was 
estimated by comparing the known volume of the human pulmonary fluid (~35 
mL) and correcting it with the body weight. 
Table 5. Values of input dose used in the model. 
Formulation D (µg) 
Liposome-encapsulated 
Ciprofloxacin 
69000 
AVT1 40500 
 
The plot of the model fitted to data for liposomes after the convergence 
criteria were met is shown in figure 29. The parameters that the model estimates 
to fit the data points are given in table 6.   
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Figure 29. Model fit to data for pharmacokinetic studies done with liposomes. 
 
Table 6. Unknown parameters estimated for pharmacokinetic study with liposomes 
Parameter Value (±sd) 95% confidence interval 
α (µg) 549.54 (±361.2) 352.03 652.53 
kLips (hr-1) 0.0024 (±0.003) -0.006 0.01 
kL0 (hr-1) 1.67 (±1.33) -2.01 5.35 
kL (hr-1) 0.012 (±0.013) -0.023 0.047 
 
Upon instillation of the liposomes, the value of α indicated that 0.8% of 
the encapsulated drug leaked from the particles and appeared free in the lungs 
due to fragmentation of the particles. The first order release rate constant from 
the liposomes (kLips) was estimated to be very low. The elimination rate constant 
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of the drug from the lung (kL0) was estimated by the model to be 2 orders of 
magnitude larger than the rate constant (kL) that transfers drug from the lungs 
into the blood.  
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Figure 30. Model fit to data for pharmacokinetic studies done with AVT1. 
 
The simulation fitted to the data for the AVT1 particles is shown in figure 
30 with the unknown parameters estimated for the study are given in table 7. The 
value of ‘α’ that was estimated represented 8% of the initial drug instilled in the 
lungs. The value of α is higher than that for the liposomal treatment suggesting 
that after the instillation, the AVT are fragmented to a higher extent than the 
liposomes resulting in a higher drug leakage into the lung compartment (with 
subsequent release into the blood compartment). The fragmentation in turn may 
be caused due to the significant motion of the lungs during breathing, applying 
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shear to the AVT particles. This is not the case when it comes to the liposomes as 
they are compact and resist to a greater extent the shearing action of the lungs 
during breathing. 
Table 7. Unknown parameters estimated for pharmacokinetic study with AVT1. 
Parameter Value (±sd) 95% confidence interval 
α (µg) 3133.12 (±381.64) 2269.8 3996.44 
kAVT (hr-1) 0.035 (±0.006) 0.023        0.048 
kL0 (hr-1) 0.881 (±0.204) 0.72        2.14 
kL (hr-1) 0.006 (±0.001) 0.004        0.008 
 
The estimates suggest that AVT1 have a better release rate than the 
liposomes (kAVT > kLips). This is also supported by the higher levels of drug that is 
maintained in the blood. The marginally lower clearance rate constant of AVT1 
in comparison to the liposomes (kL0) suggests that the amount of drug that is 
cleared from the lungs is mostly free drug in the case of the AVT1 plus drug that 
may be associated with the fragments that may be formed due to the shearing 
nature of the lungs. In the case of the liposomes, the drug cleared is free drug 
plus drug encapsulated within the liposomes that may be cleared by the 
macrophages. The action of the macrophages is assumed to be lower in the case 
of the AVT1 due to their large size, with only the fragmented particles being 
taken up if they are within the size range for macrophage activity. 
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4.2. The 2nd generation of AVT (in vivo cleavable) 
The commercially available cross-linker DTSSP was identified to be 
cleavable by cysteine (acceptable for in vivo use). In this section the results of the 
studies that were undertaken in vitro to show size reduction and drug release 
upon cleavage are reported. Additionally the in vivo studies that were 
undertaken to suggest modulated release capabilities of the agglomerates made 
with this linker are also discussed. 
4.2.1. In vitro studies with blank liposomes 
4.2.1.1. Characterization of liposomes 
The size of the liposomes extruded through the 400 nm polycarbonate 
membrane, as measured by DLS was in the range of 180-340 nm with a mean 
diameter at 244 nm. These were consistent with the sizes achieved during the 
numerous undertakings for fabricating the liposomes.  
4.2.1.2. Agglomeration of liposomes with DTSSP 
Agglomerates of liposomes that were made with DTSSP were incubated 
with different amounts of cysteine at 37 0C in order to see if cleavage was 
possible. The sizes of the agglomerates were analyzed by the Fraunhofer 
diffraction method, before and after cleavage. The results of these studies are 
shown in figure 31.  The agglomerates of liposomes (50 mM lipid) made with 20 
fold molar excess of DTSSP had sizes between 3.5 – 95 µm with a mode at 19.4 
µm.  
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Figure 31. Fraunhofer diffraction analysis of liposomes agglomerated with DTSSP, and 
subsequent cleavage with cysteine at 37 0C. Agglomerates with (a) 20 mM lipid, and (b) 
1.25 mM lipid. 
 
These agglomerates were then cleaved with different amounts of cysteine 
at lipid molarities of 20 mM (figure 31a) and 1.25 mM (figure 31b). It was 
observed that the reduction in the size of the agglomerates was proportional to 
the amount of cysteine that was used. This is evident by a shift in the size 
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distributions to the smaller sizes with an increase in the fraction of particles in 
the 4-16 µm, and a fall in the fraction of agglomerates larger than 30 µm. 
However, the cleavage was not extensive, i.e. it did not result in the formation of 
parent liposomes. It was anticipated that this cleavage of the agglomerates would 
result in accelerated release of the drug. 
4.2.2. In vitro studies with carboxyfluorescein (CF) loaded liposomes 
4.2.2.1. Characterization of liposomes 
The liposomes encapsulating 5 mM CF that were extruded through 400 
nm polycarbonate membrane had a size distribution between 170-350 nm with a 
mean diameter of 241 nm. These sizes were consistent with those achieved with 
the extrusion process. 
4.2.2.2. Agglomeration of liposomes with DTSSP 
The liposomes encapsulating CF were agglomerated with DTSSP and 
were sized by Fraunhofer diffraction analysis. The size distributions are shown 
in figure 32. The agglomerates were distributed from 1-90 µm.  
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Figure 32. Fraunhofer analysis of agglomerates of liposomes encapsulating CF. 
 
These agglomerates were used for visual analysis of the structure of the 
agglomerate by confocal microscopy. 
4.2.2.3. Visual analysis of agglomerates by Confocal microscopy 
A montage of the slices of the one of the agglomerates that was imaged is 
shown in figure 33. The Z-stack for the slices was set at 0.5 µm. The stack size of 
the image was 36.6 µm x 36.6 µm x 7.5 µm. The pixel resolution of each slice was 
512 x 512. The size of the agglomerate seen here is between 3-8 µm. The slices 
through the agglomerate indicate the presence of compact domains (bright areas) 
and porous domains (dark areas within the agglomerate). This heterogeneity in 
the structure can be attributed to two things that may be happening during the 
reaction: (1) The initial fast reaction leads to the formation of smaller compact 
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agglomerates of the liposomes, (2) the activated ligands on the liposomes present 
at the outer boundary of these compact agglomerates then form cross-links with 
the un-activated ligands on other agglomerates to form the larger agglomerate.      
 
Figure 33. Slices of confocal image of an agglomerate encapsulating carboxyfluorescein. 
Data at top right corner of each image is the Z-stack height, with Z-stack slices taken 
every 0.5 µm. 
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The image slices that were obtained were then processed and analyzed 
with ImageJ (NIH) to determine the void area fraction of the agglomerate. 
Briefly, each slice was converted to an 8 – bit grayscale image. A binary threshold 
was then applied to the resulting image. Using the Wand tracing tool in ImageJ, 
the boundary of the resulting agglomerate structure was determined. The area 
fraction of this bounded image was then determined using the built-in macro 
‘MeasureAreaFraction’. The void fraction of the agglomerate was determined to 
be 5-10% of the total area of the agglomerate.   
 
4.2.3. In vitro studies with Ciprofloxacin loaded liposomes 
4.2.3.1. Characterization of Ciprofloxacin loaded liposomes 
The sizes of the Ciprofloxacin loaded liposomes as determined by DLS 
were in the range of 140 – 350 nm with a mean at 210 nm. This was consistent 
with the sizes obtained after extrusion through the 400 nm polycarbonate 
membrane.  After removal of the unencapsulated Ciprofloxacin by dialysis the 
final concentration of Ciprofloxacin was found to be 21 mg/ml, which 
represented 80% of the initial drug used during the loading. 
The agglomerates of these liposomes made with the cysteine cleavable 
linker DTSSP were used for both in vitro and in vivo studies. 
 112 
4.2.3.2. Agglomeration of Ciprofloxacin loaded liposomes with DTSSP 
The sizes of the agglomerates as determined by the Fraunhofer diffraction 
technique are shown in figure 34. The agglomerates had a size distribution 
between 2 – 100 µm with a mode at 5.5 µm.  These agglomerates were used in 
vitro drug release experiments. 
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Figure 34. Size distribution of agglomerates of liposomes encapsulating Ciprofloxacin. 
 
4.2.3.3. Visual analysis of agglomerates by negative stain electron 
microscopy 
The agglomerates of DTSSP made in the previous section were visualized 
by negative stain electron microscopy. Figure 35 shows the negative stain 
electron microscope (EM) images of liposomes and AVT particles encapsulating 
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Ciprofloxacin. Figure 35a shows the EM image of the parent liposomes with 
diameters around 200 nm. Since the length of the PEG anchor (~7 nm) is very 
small compared to the size of the liposome, linked liposomes are in close 
proximity as shown in Figures 35b–d.  
 
Figure 35. Negative stain electron microscope images (1% uranyl acetate) taken on a 
JEOL JEM 1230. (a) liposomes at 10 K magnification, scale bar 0.2 µm; (b) agglomerate 
at 10 K magnification, scale bar 0.2 µm; (c) agglomerate at 2 K magnification, scale bar 2 
µm; (d) agglomerate at 4 K magnification, scale bar 1 µm. 
 
a b 
c d 
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The agglomerates clearly consisted of clusters of cross-linked liposomes 
incorporating high amounts of the negative stain suggesting high accessibility of 
the aqueous phase to the interior of the agglomerate structure. A heterogeneous 
structure can be seen that includes highly porous as well as compact domains 
within the agglomerate. As the compact structures were nucleated rapidly, 
diffusion-limitations dominated during the agglomeration reaction, resulting in 
the formation of porous structures of the compact “nuclei”. Similar structures are 
expected for all the agglomerates formed, since the reaction conditions for each 
were very similar. One therefore expects that drug release properties of each of 
the agglomerates would also be very similar to each other. 
4.2.3.4. Release studies 
The results of the in vitro release experiments undertaken to show 
modulated release of the drug from the agglomerates after treatment with 
cysteine are shown in figure 36. To show that the modified release from the 
agglomerates was due to cysteine alone and not due to any other factors, a third 
study was done were a volume of plain buffer equivalent to that of cysteine (50 
µl) was introduced at similar time points. Upon the introduction of cysteine into 
the dialysis bag accelerated release of drug into the external phase was observed. 
The results suggested as expected that the increased release was due to cysteine 
addition and not due to other factors. The overall release from the cleaved 
agglomerates was higher than from the agglomerates that were not cleaved.  
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Figure 36. In vitro release profiles from uncleaved agglomerates, agglomerates that were 
repeatedly cleaved with cysteine, and agglomerates treated with plain buffer. (Arrows 
indicate time points at which 50 µl of either buffer or cysteine containing buffer is 
introduced.) 
 
This result suggests that the cross-links in the agglomerates are cleaved by 
cysteine, thus exposing the interior of the agglomerate structure to the surfactant 
that consequently results in more release.  This would be analogous to the 
reduction in size of the DTSSP agglomerates observed by Fraunhofer analysis 
(figure 31) upon cleavage with cysteine. 
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4.2.4. In vivo cysteine triggered release studies 
4.2.4.1. Characterization of liposomes 
The size of the liposomes encapsulating Ciprofloxacin was in the range of 
140 – 350 nm with a mean at 210 nm. The liposomes incorporating fluorescent 
tagged lipid (used in the lipid assay from the lungs) were in the range of 177 – 
460 nm with a mean at 290 nm. 
4.2.4.2. Agglomeration of liposomes with DTSSP 
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Figure 37. Particle size distribution, by Fraunhofer Diffraction, of the agglomerates used 
in the pharmacokinetic and lipid assay studies.  
 
The particle size distributions, by Fraunhofer Diffraction, of AVT2 (DTSSP 
agglomerates of liposomes encapsulating Ciprofloxacin used in vivo) that were 
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used for the pharmacokinetic studies, and that of the agglomerates used for the 
lipid assay studies, are shown in figure 37. The agglomerate populations for 
AVT2 were distributed from 2 –120 µm with a mode at 11 µm. 
The agglomerates of DTSSP that were used for the lipid assay studies 
showed a bimodal distribution from 1 – 125 µm, with one mode at 5 µm and the 
second one at 44 µm.  
4.2.4.3. Pharmacokinetic studies in rabbits 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 200 400 600 800 1000 1200 1400 1600 1800
Time (mins)
C
ip
ro
fl
o
x
a
ci
n
 i
n
 b
lo
o
d
 (
µ
g
/m
l)
AVT2
AVT2 cleaved with cysteine
 
Figure 38. Pharmacokinetic data of AVT2 particles, with and without cysteine 
treatment. Arrows indicate time points when 1 ml cysteine (60 mg/ml) was instilled. n=3 
animals. 
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Figure 38 shows the blood levels of Ciprofloxacin after intratracheal 
instillation of the AVT 2, and AVT 2 + cysteine treatment. Each data point 
represents the mean and standard deviation of the group (3 rabbits per group). 
The difference of the means between groups was verified to be significant by 
variance analysis (Student’s t-test). A p-value less than 0.05 was used to confirm 
significant differences at the 95% confidence level. The dose of the AVT2 that 
was instilled in the rabbits for the two studies is shown in table 8. 
 
Table 8. Dose of AVT2  instilled in the lungs of rabbits. 
Formulation 
Ciprofloxacin 
Dose (mg/kg) 
Molarity of lipids 
(mM) 
Drug:Lipid 
(molar) 
AVT 2 18.31±0.62 ~50 1.07 
 
The AVT2 exhibited an initial burst in release, but the levels were lower 
compared to the study done with the free Ciprofloxacin (section 4.1.3.3). The 
AVT 2 particles exhibited a Cmax of 0.8 ± 0.07 µg/ml followed by a gradual drop 
to 0.24 ± 0.04 µg/ml in 24 hours. 
After instillation of cysteine at 90 minutes into the lungs of the rabbits an 
elevation in release rate was observed. The Cmax attained due to cysteine 
instillation was 1.27 ± 0.22 µg/ml. The blood levels of drug in animals treated 
with AVT2 and then with cysteine are significantly different (p < 0.05) from those 
for the same formulation with no cysteine treatment. The systemic bioavailability 
of the AVT2 particles is clearly improved after cysteine instillation as indicated 
by the increase in the AUC. 
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A 40% increase in total release (as measured by the area under the curve, 
AUC) was caused by the cysteine instillation. After 24 hours a repeat cysteine 
instillation resulted in further triggered release. However, smaller drug amounts 
were released consistent with overall lower residual drug content in the particles 
at this extended time post administration. The triggered release due to cysteine 
addition may be attributed to the cleaving of the disulfide linkages on the DTSSP 
that links two liposomes. This breakage would result in the rupture of the 
structure of the microparticle resulting in accelerated drug release. 
 
 
Figure 39. Comparison of the pharmacokinetics of liposomes, AVT1, AVT2, and AVT2 
followed by cysteine. Study with liposomes was done over 2 days. The AVT studies were 
done over 1 day. n=3 animals. 
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A comparison of the pharmacokinetics of the AVT2 particles with the 
previous treatment of liposomes and AVT1 (section 4.1.3.3) is shown in figure 39. 
The differences in size and the nanostructure of the particles affect the release 
properties of the microparticle formed. On the basis of size AVT1 > AVT2 > 
Liposomes. A compact structure of the agglomerate would represent a high 
concentration of drug-bearing nanoparticles, which may not promote diffusive 
transport. On the other hand, a more porous, open structure would represent a 
lower concentration of drug-bearing particles, but a higher diffusive transport 
rate. Also, due to the dynamic nature of the lungs, large and loose agglomerates 
maybe more susceptible to rupture and consequent increase in drug release in 
comparison to smaller compact agglomerates. This would mean more drug being 
released into the systemic circulation. As seen in figure 39 AVT1 show higher 
release of drug into the blood as compared to AVT2. 
  
Table 9. AUC0 – 24 for each of the formulations tested. 
Formulation Dose (mg/kg) AUC0 - 24 (µg/ml.hr) 
Liposome-encapsulated 
Ciprofloxacin 
21.07 ± 1.64 8.02 ± 2.3 
AVT 1 17.05 ± 0.44 19.8 ± 0.12 
AVT 2 18.31 ± 0.62 10.45 ± 0.92 
AVT 2 + cysteine 18.56 ± 0.54 14.51 ± 2.3 
 
A comparison of the areas under the concentration-time curves (AUC0 – 24) 
for AVT1, AVT2, AVT2 + cysteine, and liposomes, is shown in Table 9. The 
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AUC’s increase with the size of the particles, suggesting that the larger particles 
have an improved systemic bioavailability in comparison to the smaller particles. 
4.2.4.4. Lipid assay of instilled formulations in rat lungs 
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Figure 40. Percentage of original dosed lipid remaining in the lungs on the basis of 
fluorescence assay of the tagged lipid. n = 3 animals. 
 
The measurement of lipid retained in the lungs indicated that there is no 
significant difference between liposomes and agglomerates (figure 40). Further, 
there is no systematic change in lipid levels during the 48 hour observation 
period; 50 – 60% of the initial amount of lipids dosed is observed in the lungs at 
all times. This is an offset of the experiment, due to losses during the processing 
of lungs tissue before the assay. This result is similar to those of Webb et al [52] 
who showed that after instillation of liposomes the amount of lipid observed in 
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the lungs during 24 hours post administration was between 76 – 106% of initial 
lipid dose suggesting that the lipids are not transported into the circulation. We 
therefore believe that the total lipid (as particles) is remaining in the lungs for the 
entire time of the experiment (48 hours), and that drug release from the particles 
into the lungs then results in the transport of free drug into the systemic 
circulation. 
4.2.4.5. Histology of rat lungs to assess inflammation 
 
Figure 41. Histological analysis of hematoxylin-eosin stained lung tissue 24 hrs after 
treatment (original magnification 100X); (A) saline-treated animals; (B) ConA-treated 
rats; (C) liposome-treated animals; (D) AVT-treated animals. n = 2 animals 
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A qualitative analysis of inflammation after instillation of the formulations 
was done by histology. The HE stained sections of lung tissue were rank ordered 
by a practicing Pathologist and are shown in figure 41.  
In saline-treated rats (figure 41A), the lung tissue was observed to be 
almost entirely normal. The ConA-treated (Concanavalin A) rats (figure 41B) 
demonstrated extensive pneumonic changes in their lungs. A bronchiole and 
adjacent alveoli showed mixed inflammatory cell infiltrates including 
neutrophils and lymphocytes, accompanied by alveolar hemorrhage. In the 
liposome-treated animals (figure 41C), patchy lymphocytic infiltrates were noted 
around a bronchiole, blood vessels, and in the interstitium in the left upper lobe 
of one of the rats receiving the liposomes. In AVT-treated animals (figure 41 D), 
the majority of the lung tissue in the rats had a normal appearance. This 
suggested that the AVT particles do not elicit a major inflammatory response, 
and are therefore safe to be used in therapy. The reason for this may be 
attributed in part to the large size of the AVT particles and also the fact that they 
are composed of phospholipids, which is a major component of the lung 
surfactant. 
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4.2.4.6. Cytokine assay from rat lungs as a measure of inflammation 
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Figure 42. Levels of cytokines detected 48 hours after the different treatments (n = 3 
animals) 
 
The levels of cytokines that were assayed for the different treatments are 
as shown in figure 42. As expected for the ConA treatment the levels of the 4 
cytokines that were assayed were higher than the levels of the respective 
cytokines for the other treatments. The IFN-γ levels were detected only for the 
ConA treatment. The IL-2 levels for the liposomal and AVT treatment were 
comparable to the saline treatment. The TNF-α levels of the liposomes and AVT 
particles were approximately 5 times the levels of the saline treatment. No IL-6 
was detected in the saline treated animals. The levels of the respective cytokines 
were similar for the liposomal and AVT treatment. Some level of inflammation 
was expected due to the instillation of foreign material into the lungs; however 
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these levels are much lower than the ConA treatment, which suggest that these 
treatments do not elicit a huge inflammatory response and support the findings 
from the histological analysis.  
4.2.5. In silico study of Ciprofloxacin pharmacokinetics 
 
Figure 43. Model fit to experimental data for (a) AVT2, and (b) AVT2 + Cysteine. 
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The results of the model that was fitted by the SAAM II software to the 
experimental pharmacokinetic data (section 4.2.4.3) for the AVT2 particle 
treatment are shown in figure 43.  The input dose ‘D’ (known parameter) for the 
AVT2 particles was 46783 µg. The unknown parameters that were estimated for 
the AVT2 treatment (figure 43a) are shown in table 10.  
Table 10. Unknown parameters estimated for pharmacokinetic study with AVT2. 
Parameter Value (±sd) 95% confidence interval 
α (µg) 1116.27 (±36.9 ) 1035.77 1196.76 
kAVT (hr-1) 0.0027 (±0. 002) -0.001 0.006 
kL0 (hr-1) 0.42 (±0.16) 0.12 0.91 
kL (hr-1) 0.006 (±0.000) 0.005 0.008 
 
The value of α that was estimated represents 2.4% of the initial amount of 
drug dosed. A comparison of the kAVT values of AVT2 with the liposomes 
(section 4.1.4) suggests that the diffusion rate of the drug is similar. The 
elimination rate constant (kL0) is lower than the liposomes, suggesting that in 
addition to the free drug being cleared, the clearance due to macrophages is 
lower.  
For the AVT2 followed by cysteine treatment the values of α, kAVT, and kL 
were fixed. Due to instillation of cysteine, a cleavage of the linkages between the 
liposomes was expected and hence a leakage of drug (represented by α’’) was 
assumed due to the fragmentation in the structure of the microparticle. Also, 
because of the cleavage and fragmentation the elimination of the AVT2 would be 
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different due to the changes in sizes; hence kL0 was also estimated assuming that 
it would be different from the treatment with only AVT2. The values of these 
estimated parameters are shown in table 11. 
Table 11. Unknown parameters estimated for pharmacokinetic study with AVT2 + 
cysteine. 
 Parameter Value (±sd) 95% confidence interval 
α’’ at 90 minutes (μg) 2240.92 (±530.5 ) 1103.12 3378.72 
α’’ at 24 hrs and 35 
minutes (μg) 
469.1 (±400.53) -390.04 1328.21 
kL0 (hr-1) 0.853 (±0.231) 0.356 1.349 
 
The value of α’’ at 90 minutes was estimated to be 10% of the drug that 
remained in the lungs at 90 minutes. The value of α’’ at 24 hours and 35 minutes 
was estimated to be 2.3% of the drug that remained in the lungs at that time 
point. The model estimated that the elimination of drug from the lungs (kL0) was 
higher in the case of the treatment with agglomerates followed by cysteine. This 
suggested that the clearance of the drug (due to lymphatic or macrophage 
clearance) is increased after the cleavage.  
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Chapter 5 
Conclusions and Future work 
5.1. Conclusions 
In the preliminary studies that were undertaken [38], the use of different 
cross-linkers was investigated in order to form agglomerates of nano-sized 
liposomes. Keeping in mind the modulation of release of drug from these 
microparticles after instillation in the lungs; DTBP, a thiol cleavable linker was 
extensively studied. Large microparticles were fabricated exhibiting diameters of 
10’s of microns. The sizes of the agglomerates could be controlled by the 
stoichiometry of the reaction (e.g. by changing either the lipid molarity of the 
parent liposomes or the amount of the linker), and the conditions of the reaction 
(e.g. pH). By following different agglomeration protocols agglomerates of 
different size distributions were achieved with geometrical diameters ranging 
from 2-140 μm. 
The aerodynamic properties of there large agglomerated particles were 
determined by cascade impaction study, which is a recommended USP method 
that is used by industry to test the aerodynamic properties of drug particles that 
are used as an inhalation therapy. It was observed that the large agglomerates 
had aerodynamic diameters in the respiratory range (1-5 μm). The size 
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characterization upon nebulization showed that the agglomerates were largely 
intact and only a small fraction of them were disrupted. Additionally, the 
nebulized agglomerates retained most of the encapsulated drug. These results 
suggested that the agglomerates remained intact during the nebulization process. 
The in vitro release experiments from the agglomerates of the 1st 
generation showed that by the introduction of a cleaving agent that breaks the 
linkages between the liposomes within an agglomerate modulation in the release 
of the drug could be achieved. However, the cleaving agent used was DTT, 
which is not a suitable candidate for use in vivo. 
In order to bring about post-administration modulation of drug release in 
vivo, cross-linkers that can be cleaved in vivo were researched. DTSSP a 
commercially available linker was found to be cleavable by cysteine (acceptable 
for in vivo use). The in vitro experiments carried out with this linker suggested 
that the agglomerates of liposomes made with this linker are cleavable by 
cysteine. In vitro release experiments suggested that a modulation in release 
could be achieved by the cleavage of the cross-links with cysteine. 
An analysis of the agglomerates by confocal microscopy and negative 
staining electron microscopy suggested a heterogeneous structure that included 
highly porous as well as compact domains within the agglomerate. As the 
compact structures were nucleated rapidly, diffusion-limitations dominated 
during the agglomeration reaction, resulting in the formation of porous 
structures of the compact “nuclei”. The void fraction within the agglomerates 
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was estimated to be between 5-10% of the entire agglomerate. This porous 
property of the agglomerate also supports the lower aerodynamic diameters (by 
cascade impaction) exhibited by the agglomerates with large geometric 
diameters.  
The in vivo experiments showed that, when the AVT particles of DTSSP 
were cleaved by cysteine, a triggered release of Ciprofloxacin was achieved. Both 
the AVT particles and unagglomerated liposomes appear to remain in the lung 
for at least 48 hours after administration. The mechanism by which Ciprofloxacin 
is delivered to the blood therefore appears to be (1) a release of Ciprofloxacin 
from the particles into the lung fluid, followed by (2) transport of the free 
Ciprofloxacin into the bloodstream. Specifically, the transport of encapsulated 
Ciprofloxacin into the blood is not suggested by our results. In contrast, previous 
work by Wong et al. [53] showed that liposomal Ciprofloxacin was more 
effective than free Ciprofloxacin against intracellular pathogens such as F. 
tularensis, suggesting that liposomal drug was possibly transported intact into 
macrophages. However, the liposomal formulations used by Wong were 
substantially different from those used in this work, and it is possible that 
changes in the bilayer composition affect the route of clearance from the lung. 
 AVT particles also exhibited higher bioavailability than the liposomes, as 
indicated by the higher AUC for the AVT particles. This is somewhat 
counterintuitive, since one expects the higher surface area of the parent 
liposomes to result in higher release rates. However, this phenomenon has been 
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previously observed in vitro, and it is believed that the larger AVT particles, 
being subjected to larger shear forces in the lung, were disrupted more easily 
than the smaller liposomes. Thus, AVT particles are expected to have two 
mechanisms for drug release (1) diffusion of the drug out of the liposomes 
themselves and (2) bulk leakage due to bilayer disruption. This mechanism is 
consistent with the repeated observation that AVT particles have higher 
bioavailabilities than liposomes.  
The two AVT formulations tested in vivo also had somewhat different 
bioavailabilities. While the reasons for this are yet unclear, they are probably 
related to the different size distributions of the two AVT particle formulations. 
The in vivo non-cleavable formulation - AVT1, had larger particles than the in 
vivo cleavable AVT2, and hence was prone to a larger extent of disruption and 
subsequent drug leakage, due to the shearing forces of the lung than the smaller 
AVT2. Thus, AVT1 had a higher release and bioavailability. 
Cleavage of the links in AVT2 by the administration of exogenous cysteine 
caused an immediate increase in Ciprofloxacin release. Further, the release rate 
appears to remain at this elevated level, reflected by an increased blood 
concentration of Ciprofloxacin at subsequent times. The cumulative release, 
measured by the AUC, is also higher for the cleaved formulation, consistent with 
this overall increased release rate. 
The toxicity studies that were done by histology and cytokine analysis 
indicate that the AVT particles did not elicit a major inflammatory response. This 
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was supported by lower infiltration of neutrophils and lymphocytes. The 
cytokine levels were low as well. These low levels of inflammation can be 
attributed to the phospholipid composition of the particles which is similar to 
that of the surfactant that lines the lungs. 
This study is the first demonstration of in vivo modulated release of drug 
in the lungs. Though the formulations were instilled into the lungs of animals, 
the aerodynamic characteristics of the particles suggest that the platform that has 
been developed holds great promise for delivering drugs into the lungs of 
humans.  
5.2. Future work 
The technology in its present form is capable of being delivered by 
nebulizers. An optimal nebulizer for delivering these agglomerates with minimal 
structural damage needs to be evaluated. This technology can also be applied to 
MDIs and DPIs, but issues of drying the particles need to be kept in mind. 
Drying the liposomes would destroy the integrity of the bilayer, however, they 
can be protected with sugars [54-56] and then dried. Sugar protection is known 
to retain a layer of water in close proximity to the bilayer, thus stabilizing it. 
Though inflammation studies were performed, the cellular uptake of the 
AVT particles needs to be investigated. It would be particularly interesting to see 
if macrophages are capable of engulfing these large agglomerates. Only a single 
time point was used for the evaluation of inflammation. However, the time 
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evolution of inflammation needs to be evaluated to see if the levels remain low at 
different time points. 
Since, the platform could be used over a prolonged time period for 
treatment; chronic toxicity studies need to be undertaken. Owing to the fact that 
the acute toxicity studies showed minimal inflammation, lower levels of chronic 
toxicity are expected. 
5.3. Clinical perspectives of the work 
The AVT is a platform technology and can, therefore, be used to deliver 
therapeutic molecules to treat local lung diseases and also systemic diseases. In 
this work it was sought to see if triggered/modulated release of drug is possible 
from carriers that are administered to lungs. It was envisioned that repeated 
doses of the drug formulation could be replaced with a single dose. This is 
particularly helpful in delivering drugs that are not easily portable, and also 
where the concerns of excipient buildup in the lungs due to repeated dosing can 
be an issue. Current technologies do provide controlled release of drug, but if the 
need arises for more drug to be delivered an additional dose of the formulation 
would be required. This work showed that modulation can be achieved from the 
AVT particles by the introduction of a second agent that is easily portable and 
stable. 
The present work with Ciprofloxacin suggests that the technology can be 
used both as a prophylactic as well as a treatment, with lower drug dosages. 
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Similarly, other anti-infective drugs for treating both local as well as systemic 
diseases can be used. This could prove to be useful in biologically hot 
environments like hospitals, where noscomial infections can be prevented. This 
technology can also prove helpful by providing protection in a military combat 
situation dealing with the use of biological agents, for example weaponized 
aerosol form of anthrax.  
This work has important implications in developing particles that are 
sensitive to the product of a disease, and are thus capable of modulating drug 
release without the need for administration of additional agents. For example, if 
insulin release were to be triggered by the glucose level, it would enable a 
versatile, feedback control system for diabetics. Therefore, it was sought to 
fabricate glucose-sensitive AVT particles capable of being cleaved by elevated 
pulmonary glucose. A concanavalin A (ConA) based linkage was implemented 
between liposomes in the AVT particles. Liposomes with glycosyl groups at the 
distal ends of PEG tethers were rapidly agglomerated by ConA. Upon exposure 
of the agglomerates to free glucose, a reduction in size was observed due to 
cleavage of the links resulting from the preferential binding of ConA to free 
glucose. It was envisaged that this cleavage would result in triggered release of 
insulin from these AVT particles. Since pulmonary glucose levels are virtually 
zero in normal humans, but are elevated in diabetics the glucose-ConA system 
appeared to be a suitable candidate for auto-modulated release of insulin. The 
AVT particles made from this construct were tested in rats which showed 
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controlled and auto-modulated release of insulin [57]. Though this construct has 
limitations due to toxicity concerns of ConA, the underlying hypothesis that 
auto-modulation is possible was demonstrated. Currently, substitutes for ConA 
that are acceptable for use in vivo, like boronates, are being investigated.   
To treat local lung diseases, the particle could target a specific site of the 
lungs by appropriate adjustment of the aerodynamic properties. Additionally, it 
could “sense” an onset of the problem and trigger the release of additional drug. 
For example, the first line of asthma therapy is based on inhaled corticosteroids 
and β2 agonist catecholamines acting as bronchodilators. Once the particle 
carrying the bronchodilator deposits in the lungs, it would continuously release 
small amounts of its drug content, thus providing prophylaxis. However, once 
the particle “senses” (where the AVT particle can be made sensitive to elevated 
levels of cytokines, chemokines, etc.) an asthma attack, extra amounts of the 
bronchodilator and an anti-inflammatory drug (e.g. albuterol) could be released 
to control the condition. 
It is envisioned that this technology can be used with a variety of drugs, 
providing significant control over a disease condition and also improve patient 
compliance. 
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